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Abstract
Background: The current paper includes a systematic search of the literature, a detailed presentation of the results, and a 
grading of treatment options in terms of efficacy and tolerability/safety.
Material and Methods: The PRISMA method was used in the literature search with the combination of the words ‘bipolar,’ 
‘manic,’ ‘mania,’ ‘manic depression,’ and ‘manic depressive’ with ‘randomized,’ and ‘algorithms’ with ‘mania,’ ‘manic,’ ‘bipolar,’ 
‘manic-depressive,’ or ‘manic depression.’ Relevant web pages and review articles were also reviewed.
Results: The current report is based on the analysis of 57 guideline papers and 531 published papers related to RCTs, reviews, 
posthoc, or meta-analysis papers to March 25, 2016. The specific treatment options for acute mania, mixed episodes, acute 
bipolar depression, maintenance phase, psychotic and mixed features, anxiety, and rapid cycling were evaluated with regards 
to efficacy. Existing treatment guidelines were also reviewed. Finally, Tables reflecting efficacy and recommendation levels were 
created that led to the development of a precise algorithm that still has to prove its feasibility in everyday clinical practice.
Conclusions: A systematic literature search was conducted on the pharmacological treatment of bipolar disorder to identify all 
relevant random controlled trials pertaining to all aspects of bipolar disorder and graded the data according to a predetermined 
122 | International Journal of Neuropsychopharmacology, 2017
Copyedited by: oup
method to develop a precise treatment algorithm for management of various phases of bipolar disorder. It is important to note 
that the some of the recommendations in the treatment algorithm were based on the secondary outcome data from posthoc 
analyses.
Keywords: bipolar disorder, anticonvulsants, antidepressants, antipsychotics, evidence-based guidelines, lithium, mania, 
bipolar depression, mood stabilizers, treatment, clinical trials
Introduction
The current paper is the second in the series of The 
International College of Neuro-Psychopharmacology papers 
concerning the development of a precise algorithm and clinical 
guidelines for the treatment of bipolar disorder (BD) in adults 
for use in primary and secondary care. It includes a system-
atic search of the literature and a detailed presentation of the 
results concerning placebo-controlled randomized trials for all 
phases and aspects of BD. It also includes the grading of treat-
ment options in terms of efficacy and tolerability/safety as well 
as a precise algorithm that still has to prove its feasibility in 
everyday clinical practice.
Materials and Methods
As described in the first paper concerning the CINP treatment 
guidelines for BD, the workgroup decided that the PRISMA 
method (Hopewell et al., 2008; Liberati et al., 2009; Moher et al., 
2009) should be followed in the search of the literature. The 
method included the search for 3 kinds of papers:
a. Randomized controlled trials (RCTs; placebo controlled as 
well as clinical trials with an active comparator with the com-
pounds used as monotherapy or add-on therapy).
b. Posthoc analyses of RCTs.
c. Meta-analyses and review papers.
d. Treatment guidelines papers.
For this purpose, MEDLINE was searched to March 25, 2016 
with the following search strategies:
1. To locate RCTs, the combination of the words ‘bipolar,’ 
‘manic,’ ‘mania,’ ‘manic depression,’ and ‘manic depressive’ 
and ‘randomized’ was used.
2. Web pages containing lists of clinical trials were scanned. 
These sites included http://clinicaltrials.gov and http://www.
clinicalstudyresults.org as well as the official sites of all the 
pharmaceutical companies with products used for the treat-
ment of BP.
3. Relevant review articles were scanned and their reference 
lists were utilized (Srisurapanont et al., 1995; Yatham et al., 
1997; Davis et al., 1999; Burgess et al., 2001; Macritchie et al., 
2001, 2003; Bech, 2002, 2006; Rendell et  al., 2003; Gijsman 
et al., 2004; Fountoulakis et al., 2005; Gao et al., 2005; Cipri-
ani et al., 2006a, 2006b, 2011; Rendell et al., 2006; Smith et al., 
2007; Fountoulakis, 2008, 2012, 2015a, 2015b, 2015c; Foun-
toulakis et al., 2008a, 2009b, 2012a, 2012d; Fountoulakis and 
Vieta, 2008; Yildiz et al., 2010; Nivoli et al., 2011; Tarr et al., 
2011; Nivoli et al., 2012).
4. The MEDLINE was searched with the combination of key-
words ‘guidelines’ or ‘algorithm’ with ‘mania,’ ‘manic,’ ‘bipo-
lar,’ ‘manic-depressive,’ or ‘manic depression.’
5. The treatment guidelines were also scanned and their refer-
ence lists were utilized.
It is difficult to locate unpublished studies, especially old ones, 
and even more difficult to retrieve their results. Thus, the main 
focus of this paper was on published studies that would have been 
peer-reviewed, are typically of higher quality, and provide more 
details than meeting abstracts or conference reports. However, 
whenever an unpublished trial was located, it is mentioned in 
that specific part of the manuscript. The authors decided not to 
seek additional information concerning unpublished trials from 
manufacturers as this might increase the retrieval bias.
Eventually the efficacy data were graded on the basis of 
a method developed by the authors and described in the first 
paper of the CINP guidelines for BD, that is also shown in Table 1. 
Agents were graded on the basis of safety and tolerability, and 
these grades are also shown in Table 1.
The PRISMA chart of the search process is shown in Figure 1 
concerning RCTs and in Figure  2 concerning guidelines. 
Ultimately the current report was based on the analysis of 57 
papers related to guidelines and 569 published papers con-
cerning RCTs or other relevant papers (reviews, posthoc, or 
meta-analyses).
Efficacy Data
Acute Mania
The data on monotherapy and combination treatment for acute 
mania are shown in Table 2. As well, the table also includes grad-
ing of efficacy data for various features of mania such as psy-
chotic features, mixed features, agitation, etc., most of that was 
based on the posthoc analyses of RCTs.
Monotherapy
Lithium. The first study investigating the efficacy of lithium 
against acute mania was conducted in 1971, but it did not follow a 
methodology that is accepted today as scientific standard (Stokes 
et al., 1971). Since then 4 placebo-controlled RCTs using modern 
clinical trial methodology starting in 1994 have been published. All 
of them utilized a period of 3 weeks vs placebo, and if a compara-
tor was included, there was an extension phase without placebo 
(Bowden et al., 1994, 2005b; Kushner et al., 2006; Keck et al., 2009).
Overall there are 5 RCTs supporting the efficacy of lithium in 
comparison with placebo in acutely manic or mixed BD patients. 
All 5 are positive and the results are consistent. The overall 
response rate suggests a rough number needed to treat (NNT) 
around 5 to 6. The therapeutic effect appears after 7 days of treat-
ment, that is, later in comparison with antipsychotics. There are 
limited data about the effect of lithium on the core symptoms of 
mania, but there are some suggestive of an effect on psychotic 
features (Bowden et al., 2005b). Its effect specifically on mixed 
episodes is unknown, and a posthoc analysis (Swann et al., 1997) 
of one of these RCTs (Bowden et al., 1994) confirmed the efficacy 
of lithium only in classic manic but not mixed patients albeit the 
number of mixed patients was too small to allow firm conclusion. 
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It exerts a therapeutic effect on manic-psychotic symptoms, but 
probably there is no therapeutic effect on concomitant depres-
sive symptoms. The drop-out rate in these trials was comparable 
with placebo with probably more patients on placebo withdraw-
ing from the study because of lack of efficacy, while side effects 
were the more common reasons for withdrawal in patients tak-
ing lithium. The most common adverse events with lithium were 
nausea, vomiting, dizziness headache, insomnia, asthenia, con-
stipation, diarrhoea, tremor, and weight gain.
Antiepileptics. Valproate—Limited data concerning the efficacy of 
valproate in acute mania exist from earlier studies (Emrich et al., 
1980, 1981; McElroy et al., 1989). The first study with modern meth-
odology on the efficacy and safety of valproate in the treatment of 
acute mania was published in 1991 (Pope et al., 1991). Since then 
3 positive (Pope et al., 1991; Bowden et al., 1994, 2006) and 2 failed 
RCTs (Tohen et al., 2008b; Hirschfeld et al., 2010) were published. 
Another study on a heterogeneous sample consisting of bipolar 
spectrum disorder patients was negative (McElroy et al., 2010a). 
A posthoc analysis of one of the RCTs (Bowden et al., 1994) did 
not find any preferential effect for divalproex in classic vs mixed 
manic patients (Swann et al., 1997). Overall the data support the 
usefulness of valproate against acute mania, although a number 
of issues need clarification. Its effect on psychotic symptoms is 
unknown and there seems to be no effect on concomitant depres-
sive symptoms. The NNT for response is probably around 10 and 
the therapeutic effect is present after 5 to 15 days. Although the 
dosages utilized in these studies were higher than those usually 
used in everyday clinical practice (15–30  mg/kg/d), they hardly 
achieved the target serum concentrations (50–100 microg/mL). 
The most frequent adverse events were somnolence, nausea, diz-
ziness, asthenia, constipation, twitching, and vomiting.
Carbamazepine—The earlier studies demonstrating the efficacy 
of carbamazepine in acute mania were published in the 1980s 
(Ballenger and Post, 1980; Post et al., 1987). Three large clinical tri-
als using modern methodology have been published since 2000, 
all of that have confirmed the efficacy of carbamazepine (Weisler 
et al., 2004, 2005; Zhang et al., 2007).
Thus, the data concerning the efficacy and safety of carba-
mazepine at dosages 400 to 1600 mg/d and a mean plasma level 
of 8.9 μg/mL are robust. The reported NNT is approximately 5 for 
response, that starts around week 2. It is unknown whether car-
bamazepine has a beneficial effect on the core manic symptoms, 
in mixed patients, or against psychotic symptoms. There seems 
to be a beneficial effect on concomitant depressive symptoms 
only in mixed patients but not in manic patients (Weisler et al., 
2005). The most frequent adverse events related to carbamaz-
epine treatment were dizziness, nausea, somnolence, and an 
increase in total cholesterol that was composed of increases in 
both high-density and low-density lipoproteins.
Other antiepileptics—There is one negative (BIA-2093–203) 
and one fixed-dosage failed (BIA-2093–204) trial for eslicar-
bazepine (Robertson et  al., 2010). Three unpublished RCTs 
(NCT00107926, NCT00107939, and NCT00099229) concern-
ing the racemic mixture licarbazepine were also negative. 
There are 2 unpublished negative trials concerning lamotrig-
ine in treating acute manic episodes (SCAA2008/GW609 and 
SCAA2009/GW610) (Goldsmith et  al., 2003). Four trials con-
Table 1. The Method for the Grading of Data on the Basis of Efficacy and Tolerability
Grading on Basis of Efficacy
Level 1 Good research-based evidence, supported by at least 2 placebo controlled studies of sufficient 
magnitude and good quality. In case of the presence of negative RCTs, positive RCTs should 
outnumber negative ones.
Level 2 Fair research-based evidence, from one randomized, double-blind placebo controlled trial. Also 
in case one or more trials exist, however, they fail to fulfil all the criteria above (e.g., very small 
sample size or no placebo control) as well as in case of positive meta-analysis alone.
Level 3 Some evidence from comparative studies without placebo arm or from posthoc analyses.
Level 4 Inconclusive data or poor quality of RCTs
Level 5 Negative data
Grading on the basis of safety and tolerability
Level 1 Very good tolerability, few side effects that are not enduring, they do not cause significant distress, 
and are not life-threatening and they do not compromise the overall somatic health of the 
patient.
Level 2 Moderate tolerability, many side effects that could be enduring and cause significant distress, but 
they are not life-threatening although they could compromise the overall somatic health of the 
patient.
Agents with very good overall tolerability but with rare life-threatening adverse events, could be 
classified here only if the lethality risk can be essentially considered to be negligible with the 
application of procedures and protocols (e.g., laboratory testing, titration schedules etc.).
Level 3 Poor tolerability, many side effects that are enduring, cause significant distress, compromise the 
overall somatic health of the patient, or are life-threatening.
Agents with moderate overall tolerability and rare life-threatening adverse events should be 
classified here even in cases the lethality risk can be essentially considered to be negligible with 
the application of procedures and protocols (e.g., laboratory testing, titration schedules etc.)..
Recommendations for treatment (combination of efficacy and safety/tolerability)
Level 1 Level 1 or 2 for efficacy and 1 for safety/tolerability
Level 2 Level 1 or 2 for efficacy and 2 for safety/tolerability
Level 3 Level 3 for efficacy and 1 or 2 for safety/tolerability
Level 4 Level 4 for efficacy or 3 for safety/tolerability
Level 5 Level 5 for efficacy (not recommended)
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cerning topiramate were all negative (Kushner et  al., 2006). 
One small RCT evaluated the efficacy and safety of lamotrigine and 
gabapentin monotherapy vs placebo in 31 patients with refractory 
bipolar and unipolar mood disorders. Although lamotrigine dif-
fered significantly from placebo, gabapentin did not (Frye et al., 
2000). Thus the data are negative for all other antiepileptics except 
for valproic acid and carbamazepine, that suggests that there is no 
class effect concerning antiepileptics in the treatment of BD (Rosa 
et al., 2009; Fountoulakis et al., 2011b).
Antipsychotics. The earlier studies on antipsychotics supported 
the efficacy of chlorpromazine (Klein, 1967) and suggested that 
antipsychotics acted more rapidly, although lithium was more 
globally effective (Shopsin et al., 1975).
Haloperidol—The efficacy and safety of haloperidol (up to 
30 mg/d) was studied in 5 RCTs and all were positive (McIntyre 
et al., 2005; Smulevich et al., 2005; Young et al., 2009; Vieta et al., 
2010a; Katagiri et al., 2012). The results suggest a NNT roughly 
equal to 5 to 8 for response. The therapeutic effect is apparent as 
early as day 4 (Goikolea et al., 2013a). However it is important to 
note that there is a signal for the induction of depression in the 
short term (Goikolea et al., 2013b). One study reported no effect 
on the core symptoms of mania. However, although haloperidol 
Figure 1. PRISMA flowchart for RCTs literature search.
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might be particularly efficacious in psychotic patients, its effect 
on mixed patients is unknown. Adverse events most commonly 
reported with haloperidol treatment were somnolence, extrapy-
ramidal symptoms (EPS), weight gain, and constipation.
Olanzapine—There are 6 positive trials supporting the efficacy 
of olanzapine (5–20 mg/d) for the treatment of manic or mixed 
episodes and concomitant psychotic features (Tohen et al., 1999, 
2000, 2008b; McIntyre et al., 2009a, 2010b; Katagiri et al., 2012). 
The NNT is approximately around 5 for response (defined as 
a 50% drop in Young Mania Rating Scale [YMRS]). Olanzapine 
seems to have a beneficial effect on the core symptoms of mania 
and on psychotic symptoms, treats mixed patients as well as 
rapid cycling, possibly improves coexisting depressive symp-
toms, and response occurs as early as days 2 to 7. Olanzapine 
does not seem to induce a switch to depression. The most com-
mon adverse events related with olanzapine treatment were 
somnolence, dizziness, dry mouth, thirst, and weight gain. EPS 
occur but at a lower rate than with haloperidol.
Quetiapine—There exist 4 positive studies supporting the efficacy 
of quetiapine up to 800 mg/d for the treatment of acute mania 
(Bowden et al., 2005b; McIntyre et al., 2005; Vieta et al., 2010b; Cut-
ler et al., 2011). Quetiapine does not seem to induce depression; 
on the contrary there is a clear beneficial effect on concomitant 
depressive symptoms. However, there is some doubt concerning 
its efficacy against mixed episodes (such patients were excluded 
in most quetiapine trials), concomitant psychotic features, and in 
rapid cycling patients. The NNT is around 4 to 6 for response. The 
most common adverse events associated with quetiapine treat-
ment included sedation, dry mouth, somnolence, headache, dizzi-
ness, and postural hypotension.
Aripiprazole—There are 5 positive (Keck et al., 2003b, 2009; Sachs 
et al., 2006; Young et al., 2009; Kanba et al., 2014) and one nega-
tive fixed dosage study (El Mallakh et al., 2010) concerning the 
efficacy of aripiprazole 15 to 30 mg/d for the treatment of acute 
manic and mixed episodes. One study was not completed and 
reported no results. Again the effect on the core symptoms of 
mania is unknown. There is a significant effect in mixed and 
rapid cycling patients, and it also treats concomitant positive 
psychotic features and agitation. Aripiprazole does not seem to 
induce depression, but it does not seem to have any effect on 
concomitant depressive symptoms either. The NNT is approxi-
mately around 5 to 10 for response. Nausea, dyspepsia, somno-
lence, anxiety, vomiting, insomnia, light-headedness, constipa-
tion, and akathisia were the most common adverse events. There 
were no significant effects on body weight, serum prolactin, or 
QTc prolongation.
Risperidone—The efficacy of risperidone 1 to 6  mg/d for the 
treatment of acute manic and mixed episodes is supported by 
3 positive studies (Hirschfeld et  al., 2004; Khanna et  al., 2005; 
Smulevich et al., 2005). The therapeutic effect is evident from day 
3 onwards. It seems also effective in the treatment of positive 
psychotic symptoms and agitation and concomitant depressive 
symptoms. The NNT is approximately around 3 to 5 for response. 
It is unknown whether risperidone has an effect on the core 
symptoms of mania or whether it is beneficial for rapid cycling 
patients. It does not seem to induce a switch to depression. Som-
nolence, dyspepsia, nausea, and EPS were the most common 
adverse events.
Ziprasidone—Three positive studies (Keck et  al., 2003a; Potkin 
et al., 2005; Vieta et al., 2010a) support the efficacy of ziprasidone 
80 to 160 mg/d for the treatment of acute manic and mixed epi-
sodes. It has a treatment effect on the core symptoms of mania 
and on concomitant positive psychotic symptoms. It does not 
seem to have any significant effect on depressive symptoms, but 
it also does not seem to induce a switch to depression. Its effect 
Figure 2. PRISMA flowchart for treatment guidelines literature search 
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in rapid cycling patients is unknown. The NNT is approximately 6 
for response. The most common adverse events with ziprasidone 
treatment were EPS, somnolence, dizziness, anxiety, and dyspep-
sia. There were no significant effects on body weight or serum 
lipids. There was a small and clinically not significant QTc prolon-
gation reported
Asenapine—Three positive trials (McIntyre et al., 2009a, 2010b; 
Landbloom et al., 2016) support the efficacy of asenapine 10 to 
20 mg/d for the treatment of acute manic and mixed episodes 
with efficacy as early as day 2.  It is unknown whether it has a 
treatment effect on the core symptoms of mania, and while in 
one of the studies a positive effect on the total Possitive and 
Negative Symptoms Scale (PANSS) score is reported, the specific 
effect on concomitant positive or negative psychotic features is 
unknown. Also unknown is the efficacy in rapid cycling patients. 
The data are equivocal concerning the effect on depressive symp-
toms, but also it does not seem to induce depression. The NNT 
is between 6 and 12 for response. The most common adverse 
events related with asenapine treatment were EPS, somnolence, 
dizziness, sedation, fatigue, oral hypesthesia, dry mouth, weight 
gain, and EPS.
Paliperidone—Two studies (Vieta et al., 2010b; Berwaerts et al., 
2012b) provide support for the efficacy of 12  mg/d of paliperi-
done ER for the treatment of acute manic and mixed episodes, 
while the data for lower dosages is conflicting. Paliperidone is 
effective as early as day 2.  It is not reported whether it has a 
treatment effect on the core symptoms of mania, positive psy-
chotic symptoms, and depression and the effect in rapid cycling 
patients is unknown. It is unclear whether paliperidone ER 
can induce switches to depression. The most common adverse 
events related with paliperidone ER treatment were headache, 
somnolence, EPS, and prolactin elevation.
Cariprazine—Three studies (Calabrese et  al., 2015; Durgam 
et  al., 2015, 2016; Sachs et  al., 2015) confirmed the efficacy of 
cariprazine (3–12 mg daily) vs placebo in the treatment of acute 
manic or mixed episodes. The NNT for response or remission 
is approximately 4 to 7. Cariprazine is reported to improve the 
core symptoms of mania but had no effect on the Mondgomery 
Asberg Depression Rating Scale (MADRS). It improves the total 
PANSS but the specific effect on the PANSS positive subscale 
is unknown. Its efficacy in mixed and rapid cycling patients is 
unknown.
Table 2. Acute Mania/Mixed Treatment Phase, Grading on Basis of Efficacy (Treatment Phase up to 12 Weeks)
Acute Manic Episodes
Agent/modality
(alphabetical order)
Monotherapy Combination with
Effect
start
day Overall Core manic Depressive Psychotic Agitation MS Cbz Lam Li Val FGAs
Allopurinol - - - - - - 5 - - 3 - 5
Aripiprazole 2–4 1 - 5 3 - 2 - - - - -
Asenapine 2 1 - 4 - - 2 - - - - -
Carbamazepine 14 1 - 5 - - - - - - - -
Cariprazine 4 1 3 5 - - - - - - - -
Celecoxib - - - - - - - - - - 2 -
Chlorpromazine - 4 - - - - - - - - - -
Clozapine - - - - - - - - - - - -
ECT - 3 - - - - - - - - - -
Eslicarbazepine - 5 - - - - - - - - - -
Gabapentin - 5 - - - - 5 - - - - -
Haloperidol 4 1 5 5 3 3 2 2 - 2 2 -
Lamotrigine - 5 - - - - - - - - - -
Levetiracetam - - - - - - - - - - - -
Licarbazepine - 5 - - - - - - - - - -
Lithium 7 1 4 5 2 - - 2 - - - -
Loxapine inhalant - - - - - 2 - - - - - -
Medroxyprogesterone - - - - - - 5 - - - - -
Olanzapine 2–7 1 3 3 3 2 1 5 - - 1 -
Oxcarbazepine - 4 - - - - - - - 4 - -
Paliperidone 2 1 - - - - 5 - - - - -
Pimozide - 4 - - - - - - - - - -
Quetiapine 4 1 - 3 3 - 3 - - 2 - -
Risperidone 3 1 - 3 3 - 3 - - - 5 -
Tamoxifen 5 2 3 5 3 - 2 - - 2 - -
TMS - 5 - - - - - - - - - -
Topiramate - 5 - - - - 5 - - - - -
Valproate 5–15 1 5 5 - 3 - - - - - 2
Verapamil - 5 - - - - - - - - - -
Ziprasidone 2 1 3 5 3 - 5 - - - - -
Abbreviations: -, no data; Cbz, carbamazepine; ECT, electroconvulsive therapy; FGA, first generation antipsychotic; Lam, lamotrigine; Li, lithium; MS, mood stabilizer; 
TMS, transcranial magnetic stimulation; Val, valproate.
The treatment options are rated according to the rating system shown in Table 1.
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Other agents and treatment modalities.  Overall, the data for tamox-
ifen are positive; however, the total patient sample is still small 
(Zarate et al., 2007; Yildiz et al., 2008). One NIMH-sponsored clini-
cal trial (NCT00026585) has not reported results yet. One small 
3-week study was negative for verapamil (Janicak et  al., 1998). 
The data concerning repetitive Transcranial Magnetic Stimula-
tion (rTMS) are conflicting. There are two RCTs, one negative 
(Kaptsan et al., 2003) and one positive (Praharaj et al., 2009).
Summary of monotherapy trials for acute mania. Overall there are 
sufficient data in the literature to support the general efficacy 
of a number of agents in the treatment of acute mania; how-
ever, many details remain to be explored concerning many of the 
agents. Lithium, valproate, carbamazepine, haloperidol, olanzap-
ine, quetiapine, aripiprazole, risperidone, ziprasidone, asenapine, 
paliperidone, cariprazine, and probably tamoxifen are efficacious 
in the treatment of acute manic episodes. It should be mentioned 
that haloperidol probably induces depression. It is unsatisfactory 
that there are no controlled data concerning the usefulness of 
electrocunvulsive treatment (ECT).
A significant problem for the everyday clinical practice is that 
the average clinician often utilizes the so-called “class effect” 
to easily navigate among therapeutic options. However, what 
needs to be stressed is that while antipsychotics seem to possess 
a class effect specific to the treatment of acute mania (possibly 
an antidopaminergic effect; Brugue and Vieta, 2007), there is no 
such effect in anticonvulsants concerning any phase of BD (Rosa 
et al., 2009; Fountoulakis et al., 2011b).
Comparison of Agents
Lithium vs others. In 2 studies comparing lithium with valproate, 
the 2 agents were found to be equivalent. There was a tendency 
of valproate to manifest fewer adverse events and dropouts, 
but its signal for efficacy in RCTs might be driven by its effect 
in patients with mixed features (Freeman et al., 1992; Bowden 
et  al., 1994). A  similar finding restricting the efficacy of carba-
mazepine to an undefined subgroup of patients in contrast to a 
wider efficacy of lithium was reported by another study as well 
(Lerer et al., 1987). Overall the efficacy was similar to carbamaz-
epine but with fewer adverse events (Okuma et al., 1990; Small 
et al., 1991). There has been a comparison of carbamazepine with 
lamotrigine that should be considered to be a failed study (Ichim 
et al., 2000). It should be noted however that lamotrigine is not an 
effective antimanic agent.
The comparison of lithium to chlorpromazine suggested that 
although chlorpromazine acts faster and might be more effica-
cious in more agitated patients, this might be due to sedation 
alone, while lithium has again a broader effect on the core manic 
symptomatology (Platman, 1970; Prien et al., 1972; Shopsin et al., 
1975). In contrast, the comparison of haloperidol and lithium 
suggested that haloperidol had a stronger and more rapid effect, 
especially on behavior and motor activity but without seda-
tion, while lithium acted more evenly and comprehensively on 
the entire range of manic symptomatology (Shopsin et al., 1975; 
Garfinkel et al., 1980).
Lithium was found to have equal efficacy to carbamazepine 
(Lerer et al., 1987; Okuma et al., 1990; Small et al., 1991), olanzap-
ine (Berk et al., 1999; Niufan et al., 2008; Shafti, 2010), quetiapine 
(Bowden et al., 2005b; Li et al., 2008), and aripiprazole (Keck et al., 
2009). In severely psychotic patients, it seems inferior to halop-
eridol (Shopsin et al., 1975; Garfinkel et al., 1980). Overall, lithium 
has a wider antimanic effect than valproate and carbamazepine 
but a weaker effect on psychotic symptoms and a slower onset 
of action in comparison with antipsychotics. Overall, lithium 
demonstrated a more favorable adverse effect profile in com-
parison with all other agents except aripiprazole and valproate.
Valproate vs others. In comparison with lithium, valproate was 
less efficacious and with a tendency to cause fewer adverse 
events and dropouts, but its efficacy might be restricted to that 
specific group of patients with mixed features (Freeman et al., 
1992; Bowden et al., 1994). In one small study, it was superior to 
carbamazepine and had a faster onset of action (Vasudev et al., 
2000). In another study, it was superior to oxcarbazepine but with 
more frequent adverse events (Kakkar et al., 2009). It might be 
less efficacious in comparison with olanzapine and with a slower 
onset of action, but also with fewer adverse events (Tohen et al., 
2002a, 2008b; Zajecka et al., 2002).
Carbamazepine vs others. Carbamazepine was reported to be 
equally effective in comparison with lithium but with a higher 
rate of adverse events. Its efficacy appeared somewhat restricted 
to an undefined subgroup of patients in contrast to a broader 
spectrum of efficacy of lithium (Lerer et al., 1987; Okuma et al., 
1990; Small et  al., 1991). In another study carbamazepine was 
inferior to valproate and had a slower onset of action (Vasudev 
et al., 2000). In 2 other studies carbamazepine was found equal 
to chlorpromazine but with fewer adverse events (Okuma et al., 
1979) and equal to haloperidol but with a slower onset of action 
(Brown et al., 1989).
Other antiepileptics. There is one study on lamotrigine vs lithium 
that should be considered as failed probably because it was 
underpowered (Ichim et al., 2000). In another study, oxcarbaze-
pine was found to be inferior to valproate but with fewer adverse 
events (Kakkar et al., 2009).
Haloperidol vs others. The comparison of haloperidol with lithium 
suggested that haloperidol is more efficacious in severely psy-
chotic patients and exerts its effect earlier, especially on behav-
ior and motor activity but without sedation, while lithium acted 
more evenly and comprehensively on the entire range of manic 
symptomatology (Shopsin et  al., 1975; Garfinkel et  al., 1980). 
Haloperidol was found equally effective to carbamazepine but 
with a faster onset of action (Brown et al., 1989). Haloperidol had 
a faster onset of action than olanzapine but with more drop-
outs, and olanzapine was superior in the nonpsychotic patients. 
Both agents were equally effective in reducing the HDRS score 
in mixed patients and in patients with higher depressive scores. 
Switch to depression occurred significantly more rapidly with 
haloperidol than with olanzapine. More EPS were reported with 
haloperidol and more weight gain with olanzapine (Tohen et al., 
2003b; Katagiri et al., 2012). Haloperidol was reported to be over-
all superior to quetiapine and more efficacious in psychotic 
patients. In contrast to quetiapine it had no effect on depressive 
symptoms. Haloperidol-treated patients had more dropouts and 
more EPS (McIntyre et al., 2005). It was reported as not superior 
to aripiprazole and did not improve the depressive symptoms 
measured with the MADRS. In comparison with aripiprazole, 
more haloperidol-treated patients switched to depression, more 
dropped out, and EPSs were more frequent with haloperidol 
(Vieta et  al., 2005b; Young et  al., 2009). Haloperidol was found 
similarly efficacious to risperidone (Segal et al., 1998; Smulevich 
et al., 2005) and superior to ziprasidone but also with more drop 
outs and adverse events (Vieta et al., 2010a). The comparison of 
25 mg/d vs 5 mg/d haloperidol revealed that the higher haloperi-
dol dosage produced greater improvement than did the low dose 
but with more side effects (Chou et al., 1999).
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In summary, haloperidol was similar in efficacy as carbamaz-
epine (Brown et  al., 1989) and olanzapine (Tohen et  al., 2003b; 
Katagiri et  al., 2012), risperidone (Segal et  al., 1998; Smulevich 
et  al., 2005), and aripiprazole (Vieta et  al., 2005b; Young et  al., 
2009). It was found to be superior to quetiapine (McIntyre et al., 
2005) and ziprasidone (Vieta et al., 2010a) and in severely psy-
chotic patients to lithium (Shopsin et al., 1975; Garfinkel et al., 
1980). It acted faster in comparison with lithium (Shopsin et al., 
1975; Garfinkel et al., 1980), carbamazepine (Brown et al., 1989), 
and olanzapine (Tohen et al., 2003b; Katagiri et al., 2012). Overall 
it demonstrated superior efficacy in psychotic patients but less 
improvement (if any) on depressive symptoms. It also showed 
more adverse events (especially EPS), switching to depression 
and dropouts more than the comparators.
Olanzapine vs others. Olanzapine was reported to be equally 
effective to lithium but with more adverse events, mainly weight 
gain (Berk et al., 1999; Niufan et al., 2008; Shafti, 2010). It might 
be superior and faster acting in comparison with valproate 
(although this could be a function of dosage) but again with more 
adverse events (Tohen et al., 2002a, 2008b; Zajecka et al., 2002). 
It was found to be similar in efficacy to haloperidol but with a 
slower onset of action and fewer dropouts. The data suggest that 
during the acute phase both agents were equally effective in 
reducing the HDRS score in mixed patients and in patients with 
higher depressive scores. More EPSs were registered with halop-
eridol and more weight gain with olanzapine (Tohen et al., 2003b; 
Katagiri et al., 2012). Olanzapine was found superior to asenap-
ine in manic and mixed patients and also significantly improved 
the MADRS score, that asenapine did not. Olanzapine-treated 
patients had more weight gain (McIntyre et al., 2009a, 2010b).
Olanzapine was found to have similar efficacy as risperi-
done in patients without psychotic features in terms of YMRS, 
HAM-D, and MADRS change. The 2 agents were also equal in the 
subgroup of rapid cycling patients. Fewer olanzapine-treated 
patients dropped out of the head-to-head comparison but there 
was more weight gain in the olanzapine group (Perlis et  al., 
2006b). Finally, an unpublished study of olanzapine vs ziprasi-
done (NCT00329108) was stopped prematurely due to poor 
recruitment (2009).
Quetiapine vs others. Quetiapine is reported to be comparable with 
lithium but with more dropouts and adverse events (Bowden 
et al., 2005b; Li et al., 2008). Also it is reported to be inferior to 
haloperidol, with fewer dropouts and less frequent EPS, and also 
less efficacious in psychotic patients. In contrast to haloperidol 
it had an effect on depressive symptoms (McIntyre et al., 2005).
Quetiapine is reported to be equal to paliperidone and both 
agents had a similar effect in manic and mixed patients. Body 
weight increase was more frequent in the quetiapine group, but 
more patients with paliperidone switched to depression (Vieta 
et al., 2010b).
Other antipsychotics. Chlorpromazine was found equal to pimoz-
ide with faster action, probably due to its greater sedative effect. 
Sedation was the side effect most frequent with chlorpromazine 
and EPS were more frequent with pimozide (Cookson et al., 1981).
The following studies have already been reported and dis-
cussed above; however, it is important to consider them again 
from a reverse angle. Risperidone was found equal to haloperidol 
(Segal et al., 1998; Smulevich et al., 2005) and olanzapine (Perlis 
et  al., 2006b). Aripiprazole was found equal to lithium (Keck 
et  al., 2009) and haloperidol (Vieta et  al., 2005b; Young et  al., 
2009). Asenapine was found inferior to olanzapine (McIntyre 
et al., 2009a, 2010b) and paliperidone equal to quetiapine (Vieta 
et al., 2010b). There is one unpublished study comparing ziprasi-
done with olanzapine that did not report any results (2009) and 
another one finding it inferior to haloperidol (Vieta et al., 2010a). 
Finally, there are 2 studies comparing chlorpromazine with lith-
ium (Platman, 1970; Prien et al., 1972) and one with carbamaz-
epine (Okuma et al., 1979), suggesting equal efficacy.
Summary of the comparison of agents. Overall, comparison stud-
ies suggest that the greater the efficacy the more frequent the 
adverse events are. Although there are no sufficient data to sup-
port a big difference between agents, it seems that antipsychot-
ics and lithium are more efficacious than valproate and carba-
mazepine unless a loading strategy for these anticonvulsants 
is applied. Also it seems clear that antipsychotics act earlier in 
comparison with the other compounds. The effect on depres-
sive symptoms is unclear, but it seems that haloperidol-treated 
patients might switch more often to depression.
Earlier studies suggested that lithium could be specifically 
useful against the more “classic” cases of euphoric mania, while 
antiepileptics might have a better efficacy for patients with 
mixed features and those with comorbidity. This is not sup-
ported by more recent data (Fountoulakis et al., 2012b). A factor 
that could have affected the results is the so-called lithium-dis-
continuation-related refractoriness (Post et al., 1992), because of 
that patients enrolled in RCTs could constitute a sample more 
refractory to lithium treatment than expected. However, the 
assumption for the existence of lithium-discontinuation-related 
refractoriness is not supported by studies reporting that even 
when samples enriched for lithium refractoriness were used, 
no inferiority of lithium to the other agent was documented 
(Bowden et al., 1994). Also a recent meta-analysis of all published 
cases concluded that there is not sufficient data to support such 
a concept (de Vries et al., 2013).
Combination and Add-On Treatment
Several studies examined the efficacy and safety of agents given 
not as monotherapy but combined treatments. The study sam-
ples range from patients being refractory to an initial treatment 
to drug-naive patients. In the first instance, an agent is used as 
adjunct or add-on therapy on a preexisting treatment to that 
the patient has shown unsatisfactory response. In the second 
instance the study tests a combination treatment against mono-
therapy and both agents are initiated simultaneously. Although 
essentially both designs provide information on how to treat 
patients with an unsatisfactory response to monotherapy, the 
conclusions and the generalizability might differ.
Combination Treatment
Adding valproate to First Generation Antipsychotics (FGAs; halo-
peridol or perazine in this study) produced higher response rates 
in manic patients (70% vs 46%) compared with FGA plus placebo 
(Muller-Oerlinghausen et al., 2000). Similarly, combination of lith-
ium (600–1800 mg/d) and quetiapine XR (400–800 mg/d) was supe-
rior to quetiapine plus placebo (Bourin et al., 2014) in treating acute 
mania. Three studies that reported on combinations of mood sta-
bilizing agents with haloperidol vs haloperidol monotherapy are 
equivocal as the outcome depended on the haloperidol dosage 
(Garfinkel et al., 1980; Klein et al., 1984; Chou et al., 1999).
Other studies reported on the efficacy of an antipsychotic 
agent and a mood stabilizer in comparison with mood stabilizer 
alone. In general, antipsychotic and carbamazepine combina-
tion is not superior to carbamazepine alone, primarily due to 
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the effect of carbamazepine inducing the metabolism of antip-
sychotics in the combination group, thus resulting in lower 
plasma levels of antipsychotics. One 6-week international trial 
of olanzapine (10–30 mg/d) vs placebo add on to carbamazepine 
(400–1200 mg/d) was negative. In the olanzapine group, however, 
the triglyceride levels were significantly higher and potentially 
clinically significant weight gain occurred more frequently. 
Furthermore, carbamazepine significantly reduced olanzapine 
serum concentrations (Tohen et al., 2008a). Similarly, in another 
study, carbamazepine significantly reduced the serum levels of 
risperidone (Yatham et al., 2003) that contributed to the negative 
findings of this study on the primary efficacy measure.
Overall the data on the combination of lithium with other 
agents support the conclusion that the combinations of lithium 
with haloperidol, lorazepam, carbamazepine, tamoxifen, and 
allopurinol are superior to lithium alone, but not the combina-
tion of lithium plus ziprasidone or dipyridamole. Most of these 
combinations had more adverse events in comparison with 
monotherapy (Garfinkel et  al., 1980; Lenox et  al., 1992; Small 
et  al., 1995; Weisler et  al., 2003; Bowden, 2005; Machado-Vieira 
et al., 2008; Amrollahi et al., 2010). Adding allopurinol to treat-
ment as usual was not more effective compared with treatment 
as usual (Weiser et  al., 2014). On the contrary, positive results 
were reported by the addition of 400 mg/d celecoxib on valproate 
in nonrapid cycling and nonpsychotic patients (Arabzadeh et al., 
2015) but negative when added on ECT (Kargar et al., 2015).
A number of trials investigated the combination of an atypi-
cal antipsychotic or other agents with addition of an agent on 
top of lithium or valproate, since these 2 constituted the back-
bone of the treatment of BD for decades. Overall the data are 
in support of combining lithium or valproate with asenapine, 
olanzapine, risperidone, haloperidol, and tamoxifen but negative 
concerning gabapentin and medroxyprogesterone (Pande et al., 
2000; Sachs et al., 2002; Yatham et al., 2003; Kulkarni et al., 2006; 
Szegedi et al., 2012; Kulkarni et al., 2014; Xu et al., 2015b). The 
addition of folic acid to valproate has equivocal support (Behzadi 
et al., 2009) and the addition of omega-3 fatty acids has negative 
data (Chiu et al., 2005). Adding the herbal agent Free and Easy 
Wanderer Plus (FEWP) on carbamazepine was not better than 
carbamazepine alone, but it was in comparison with placebo 
while carbamazepine monotherapy was not. Technically it does 
not support the use of FEWP in acute mania, but a number of 
other interpretations also exist, for example that adding FEWP 
compensates for the drop in carbamazepine levels (Zhang et al., 
2007). However, that study did not define an a-priori primary out-
come and therefore its quality is low. Finally, one study suggested 
that the valnoctamide plus risperidone combination was more 
effective than risperidone alone (Bersudsky et al., 2010).
In summary, there are few but still important data suggest-
ing that specific combinations are superior to monotherapy 
in nonrefractory or otherwise selected samples, although it is 
difficult to assess the quality of many study samples. Despite 
the very small number of trials and the problems with the 
data quality, one could generalize that the combination of an 
antipsychotic plus lithium or valproate is superior to lithium or 
valproate alone, with the caveat of greater side-effect burden. 
Tamoxifen and probably allopurinol are also valuable agents to 
use in combination with mood stabilizers.
Add-On Treatment
In patients refractory to haloperidol treatment, the addition of 
phenytoin has been shown to be beneficial (Mishory et al., 2000). 
In patients refractory to lithium, adding 600 to 1200 mg/d car-
bamazepine or oxcarbazepine improved the outcome (Juruena 
et  al., 2009), but that study was of poor quality, questionable 
phase of the disorder and outcome, and without any a-priory 
defined primary outcome. Adding lovastatin on lithium was neg-
ative (Ghanizadeh et al., 2014).
In patients refractory to lithium, valproate, or carbamazepine, 
it is beneficial to add haloperidol, olanzapine, quetiapine, ari-
piprazole, or asenapine (Szegedi et al., 2012) (Sachs et al., 2002, 
2004; Tohen et al., 2002b; Yatham et al., 2007; Vieta et al., 2008b) 
but not ziprasidone, topiramate, risperidone, or paliperidone 
(Roy Chengappa et al., 2006; Berwaerts et al., 2011; Sachs et al., 
2012a, 2012b; Moosavi et al., 2014). One study that used a mixed 
population with some patients entering after a minimum of 2 
weeks of mood stabilizer therapy, and others starting a mood sta-
bilizer and risperidone in parallel, provided inconclusive data for 
risperidone (Yatham et al., 2003) as the results were likely con-
founded by the effects of carbamazepine on serum levels of ris-
peridone. Allopurinol was not beneficial in patients refractory to 
lithium, valproic acid, carbamazepine, or atypical antipsychotic 
medications (Fan et al., 2012), although there are some data sug-
gesting a beneficial effect on patients refractory to valproate 
(Jahangard et al., 2014). Adding the melatonin agonist ramelteon 
was also not efficacious in patients refractory to treatment as 
usual (McElroy et al., 2010b). There is only one sham-controlled 
trial of ECT as adjunctive treatment to chorpromazine (600 mg/d) 
in 30 acutely manic patients. That study supported the efficacy of 
ECT with a faster rate of improvement (Sikdar et al., 1994)
A recent placebo-controlled 4-week RCT in 180 acutely manic 
patients supported the efficacy and safety of the purinergic agents 
allopurinol (600 mg/d) and dipyridamole (200 mg/d) as adjunctive 
to lithium in acute bipolar mania (Machado-Vieira et  al., 2008). 
Folic acid was also found to be useful as an adjunct to valproate in 
treating acute mania (Behzadi et al., 2009). There is one 5-week trial 
from Israel on 32 recently admitted manic inpatients that com-
pared valnoctamide (600–1200 mg/d; n = 15) vs placebo (n = 17) on 
top of risperidone (1–6 mg/d). All medications were started at day 
1. In all efficacy measures the valnoctamide plus risperidone com-
bination was more effective than risperidone plus placebo from 
week 3 to week 5. Valnoctamide is an anticonvulsant analogue of 
valproate that does not undergo biotransformation to the corre-
sponding free acid, and in mice it has been shown to be distinctly 
less teratogenic than valproate (Bersudsky et  al., 2010). A  pilot 
8-week study in 21 acutely manic outpatients on the usefulness of 
adjunctive ramelteon in acute mania/mixed states failed (McElroy 
et al., 2010b), while another 2 on the cholinesterase inhibitor done-
pezil were negative (Eden Evins et al., 2006a; Chen et al., 2013).
Overall, the data in partial responders or refractory patients 
support the addition of specific antipsychotics to lithium or val-
proate and also the use of allopurinol and the combination of 
lithium with carbamazepine or maybe oxcarbazepine.
Posthoc Analyses and Meta-Analytic Studies
A very important posthoc analysis of individual patient data 
reported that patients with impaired insight (as measured with the 
use of item 11 of the YMRS) responded better; therefore treatment 
should be initiated immediately and the therapist should not wait 
until the patient gains sufficient insight (Welten et al., 2016).
Overall, posthoc and meta-analytic studies confirm the effi-
cacy of specific agents vs placebo (Emilien et al., 1996; Yatham 
et al., 2004; Perlis et al., 2006a; Scherk et al., 2007; Tamayo et al., 
2010) and also confirm the superiority of antipsychotics vs lith-
ium, valproate, and carbamazepine both in terms of faster onset 
of action but also in terms of the overall outcome in the short-
term treatment of acute mania. However, they also confirm that 
this higher efficacy comes with the cost of more frequent adverse 
events, mainly EPS, weight gain, and somnolence (Correll et al., 
2010; Tarr et al., 2010). These conclusions should be received with 
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caution, taking into consideration both the limitations of meta-
analytical methods and the frequent conflicting results.
Haloperidol might be the fastest acting of all (Goikolea et al., 
2013a) but also the most likely one to induce depression (Goikolea 
et al., 2013b). Olanzapine was efficacious against mixed episodes, 
depressive symptoms, and psychotic features as well as in rapid 
cycling patients (Baker et  al., 2002; Baldessarini et  al., 2003b; 
Chengappa et  al., 2003; Suppes et  al., 2005, 2008b). Quetiapine 
was proven efficacious for all YMRS individual items, depressive 
symptoms, and also against psychotic features (Vieta et al., 2005a). 
Risperidone vs placebo caused higher remission rate and the 
drop-out rate because lack of efficacy was lower, while the drop-
out rate because of adverse events was similar to that of placebo 
(Gopal et al., 2005). Asenapine was efficacious against depressive 
symptoms (Szegedi et al., 2011) and mixed episodes (Azorin et al., 
2013; McIntyre et al., 2013) and has an effect on the core symp-
toms of mania (Cazorla et al., 2013). Aripiprazole had no effect in 
patients aged >55 years but was effective against psychotic symp-
toms (Suppes et al., 2008b; Fountoulakis et al., 2009a; Sayyaparaju 
et al., 2014). Aripiprazole, lithium, and haloperidol overall are not 
efficacious against concomitant depressive features (Ostacher 
et al., 2015b). Ziprasidone was efficacious against dysphoric mania 
(Ketter et al., 2010; Stahl et al., 2010). The data of oxcarbazepine 
appear to be insufficient (Vasudev et al., 2011). A posthoc analy-
sis of a lithium study (Bowden et al., 1994) confirmed the efficacy 
of lithium in classic manic but not mixed patients (Swann et al., 
1997), while another posthoc study confirmed the lack of efficacy 
of eslicarbazepine although there seems to be some signal in the 
secondary outcomes (Grunze et al., 2015).
Meta-analytic studies also suggest that combination treatment 
is superior to monotherapy at the cost of more frequent adverse 
events; however, these meta-analyses do not distinguish between 
add-on and combination studies and populations (Scherk et  al., 
2007; Smith et al., 2007; Tarr et al., 2011; Ogawa et al., 2014). One 
meta-analysis reported that studies outside the United States had 
higher effect size and the baseline YMRS predicted the outcome 
(Tarr et al., 2011), probably because of a mathematical structural 
coupling effect (Fountoulakis and Kontis, 2012). Year of study pub-
lication was not associated with YMRS score change. Furthermore, 
the study size, number of study sites, YMRS score required for 
study entry, inclusion of patients with mixed mania or treatment 
resistance, and inclusion of inpatients vs outpatients had no sig-
nificant influence on the outcome (Tarr et al., 2011).
Two recent meta-analyses attempted to rank antimanic 
agents according to efficacy. The first one utilized the method of 
multiple-treatments meta-analysis and reported that the rank-
ing in terms of efficacy was haloperidol, risperidone, olanzapine, 
lithium, quetiapine, aripiprazole, carbamazepine, asenapine, val-
proate, and ziprasidone. According to that meta-analysis, overall, 
antipsychotics were significantly more effective than mood sta-
bilizers; however, the results of that analysis do not fully sup-
port such a conclusion (Cipriani et al., 2011). This meta-analysis 
has been criticized both concerning the overall methodology but 
also concerning the incomplete list of RCTs that was utilized 
(Fountoulakis and Siamouli, 2012). A more balanced meta-anal-
ysis confirmed that the response to antipsychotics was greater 
and more rapid in comparison with lithium, valproate, or carba-
mazepine, but it did not confirm any difference between halop-
eridol and second generation antipsychotics (Yildiz et al., 2010). 
A more recent network meta analysis did not support the supe-
riority of any agent vs another except for risperidone vs aripipra-
zole and valproate (Yildiz et al., 2015).
A meta-analysis that pooled data from 9 randomized, double-
blind, placebo-controlled, acute studies of ziprasidone reported 
that the discontinuation rate due to adverse events or 7% or 
greater weight gain between ziprasidone and placebo was not 
significant for all psychiatric conditions. In acute mania the 
risk for akathisia with ziprasidone had a number needed to 
harm (NNH) = 12, the risk for overall EPS had a NNH = 12, and the 
reported somnolence had NNH = 7 (Gao et  al., 2013). Finally, a 
recent network meta-analysis reported that aripiprazole, olan-
zapine, quetiapine, risperidone, and valproate had less all-cause 
discontinuation rates than placebo and that there is a similar 
efficacy profile for haloperidol, second-generation antipsychot-
ics, and mood stabilizers (Yildiz et al., 2014) while a meta-analy-
sis of combination studies confirmed the higher rate of adverse 
events in comparison with monotherapy (Galling et al., 2015).
The analysis of the data concerning the usefulness of the 
cholinesterase inhibitors galantamine and donepezil as well 
as the glutamate receptor antagonist memantine was negative 
(Veronese et al., 2016).
Acute Bipolar Depression
Bipolar depression is not well studied, and the common practice 
among clinicians is to extrapolate the clinical data and wisdom 
from the treatment of unipolar to bipolar depression. However, 
the clinical trials that examined the efficacy of various agents 
have raised questions about the validity of such strategy.
The agents are listed below in a historical sequence with lith-
ium and anticonvulsants first, then antidepressants, and finally 
with antipsychotics on the basis of the year of the first study they 
were investigated.
The data on monotherapy and combination treatment for 
acute bipolar depression and its special characteristics are 
shown in Table 3.
Monotherapy
Lithium. The earlier studies on the efficacy of lithium against 
bipolar depression provided some positive data but are difficult 
to interpret (Goodwin et al., 1969, 1972; Greenspan et al., 1970; 
Stokes et al., 1971; Noyes and Dempsey, 1974; Noyes et al., 1974; 
Baron et al., 1975; Mendels, 1976; Donnelly et al., 1978; Srisura-
panont et  al., 1995). There is only one modern and rigorously 
conducted RCT (EMBOLDEN I) and it was negative for lithium 
while positive for quetiapine. While in this particular study 
the mean lithium serum levels were 0.61 mEq/lt, with 34.9% of 
patients having levels <0.6 mEq/lt, a posthoc analysis reported 
that the results were negative also in patients with lithium levels 
>0.8 mEq/lt and also in patients who completed the study. Fur-
thermore, lithium level did not correlate with change in depres-
sion rating scores (Young et al., 2010).
Antiepileptics. Valproate—There are 3 small positive trials (Davis 
et al., 2005; Ghaemi et al., 2007; Muzina et al., 2010) and one failed 
(Sachs et al., 2001), that is not published and can be assessed only 
through 2 meta-analytic papers (Bond et  al., 2010; Smith et  al., 
2010). Taken together, these studies suggest that there are some 
data (though somewhat inconsistent and not sufficient), coming 
from small trials supporting the efficacy of valproate (titrated up to 
2500 mg/d) in bipolar depression, especially in BD-I patients and on 
the core symptoms of depression. There is possibly some efficacy 
against concomitant anxiety.
Carbamazepine—The old, small withdrawal studies concerning 
carbamazepine efficacy against bipolar depression were positive 
(Ballenger and Post, 1980; Post et al., 1983, 1986) but also suggested 
that plasma levels do not correlate with the treatment effect 
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(Post et  al., 1983). A  more recent 12-week double-blind, rand-
omized, placebo-controlled study from China had equivocal 
results (Zhang et al., 2007).
Lamotrigine—There are 5 trials that investigated the efficacy 
and safety of lamotrigine in the treatment of acute bipolar 
depression (SCA100223/NCT00274677, SCA30924/NCT00056277, 
SCA40910, SCAA2010, and SCAB2001). One included BD-II 
patients alone and one a mixed population of BD-I and BD-II 
patients. All were negative concerning the primary outcome 
(Calabrese et  al., 1999; Goldsmith et  al., 2003; Ostacher et  al., 
2008), although in one study lamotrigine separated from placebo 
on MADRS, an important secondary outcome measure (Cala-
brese et al., 1999). A small double-blind, randomized study with 
crossover series of three 6-week monotherapy evaluations in 
a mixed unipolar-bipolar population reported that lamotrigine 
was superior to placebo (Frye et al., 2000). Overall the data are 
negative concerning the efficacy of lamotrigine in acute bipolar 
depression, although the presence of a weak signal cannot be 
ruled out.
Antidepressant Monotherapy
Despite the fact that antidepressants have established effi-
cacy in unipolar depression, that defines them as a class of 
drugs that includes different kinds of molecules, such a “class 
effect” does not appear to be present for bipolar depression 
(Fountoulakis et al., 2011b). Although the data are problematic, 
the use of antidepressants is neither encouraged nor prohib-
ited by all treatment algorithms, that however consistently 
advise the concomitant use of an antimanic agent. The current 
view is that antidepressant monotherapy should not be used 
in bipolar depression (Vieta, 2014). Older placebo-controlled 
studies were mostly positive but difficult to judge on the basis 
of modern criteria and understanding of methodology.
An early study reported superiority of tranylcypromine vs 
placebo in anergically depressed patients and suggested that 
Table 3. Acute Depression Treatment Phase, Grading on Basis of Efficacy (Treatment Phase up to 12 Weeks)
Monotherapy Combination
Anxiety
Agent/modality
(alphabetical order) Overall BD-I BD-II Depressive core MS Cbz Lam Li Val
Agomelatine - - - - 5 - - 5 5 -
Aripiprazole 3 3 - - - - - 5 - -
Armodafinil - - - - 4 - - - - -
Bupropion - - - - 5 - - - - -
Carbamazepine 3 - - - - - - - - -
Celecoxib - - - - 5 - - - - -
Donepezil 5 - - - - - - 5 - -
Escitalopram - - 2 - - - - - - -
Fluoxetine 2 - 3 - - - - 4 - -
FEWP - - - - - 4 - - - -
Gabapentin 5 - - - - - - - - -
Imipramine 3 - - - - - - 5 - -
Ketamine - - - - 2 - - - - -
Lamotrigine 3 3 3 3 - - - 2 - -
Levetiracetam - - - - 5 - - - - -
Levothyroxine (L-T4) - - - - 4 - - - - -
Lisdexamfetamine - - - - 5 - - - - -
Lithium 4 - - - - - 2 - - 5
L-sulpiride - - - - - - - 3 - -
Lurasidone 2 2 - 3 2 - - - - 3
Memantine - - - - - - 5 - - -
Modafinil - - - - 2 - - - - -
OFC 2 2 - 3 - - - - - -
Olanzapine 1 1 - 3 - - - - - -
Oxcarbazepine - - - - - - - 4 - -
Paroxetine 5 5 5 - 5 Neg - 5 5 3
Phenelzin 3 - - - - - - - - -
Pioglitazone - - - - - - - 2 - -
Pramipexole - - - - 2 - - - - -
Pregnenolone - - - - 5 - - - - -
Quetiapine 1 3 3 3 - - - - - 3
Risperidone - - - - 5 - - - - 5
TMS 5 - - - - - - - - -
Tranylcypromine 4 4 4 - - - - - - -
Valproate 3 3 5 3 - - - - - 3
Venlafaxine 4 4 4 - - - - - - -
Ziprasidone 5 5 - - 5 - 5 5 5 5
Abbreviations: -, no data; Cbz, carbamazepine; ECT, electroconvulsive therapy; FEWP, Free and Easy Wanderer Plus; Lam, lamotrigine; Li, lithium; MS, Mood Stabilizer; 
OFC, Olanzapine Fluoxetine Combination; TMS, transcranial magnetic stimulation; Val, valproate.
The treatment options are rated according to the rating system shown in Table 1.
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tranylcypromine could be efficacious against bipolar depres-
sion since anergic depression most typically occurs in BD and 
in pseudounipolar affective illnesses (Himmelhoch et al., 1982). 
However, the methodology of this study has been criticized.
The first trial reported that fluoxetine and imipramine were 
efficacious vs placebo, but the interpretation of the results of this 
study is complicated by the concomitant use of lithium, espe-
cially in the fluoxetine group (Cohn et al., 1989). A second small 
trial was negative for fluoxetine and olanzapine monother-
apy and also for the olanzapine-fluoxetine combination (OFC) 
(Amsterdam and Shults, 2005a). Another small placebo-con-
trolled, cross-over study lasting 9 months in 10 BD-II depressed 
patients suggested that escitalopram might be better than pla-
cebo as monotherapy for depression and without worsening of 
illness course (Parker et al., 2006). The only properly conducted 
study on a sample of adequate size was an international trial 
on 740 patients with bipolar depression (both BD-I and BD-II). 
This study was negative for paroxetine 20  mg/d while it was 
positive for quetiapine. However, paroxetine produced a signifi-
cant improvement in anxiety in terms of change of HAM-A scale 
score from baseline but was not efficacious concerning depres-
sive symptoms in any subgroup of patients. The most frequent 
adverse events were dry mouth, sedation, headache, insomnia, 
and nausea with paroxetine treatment (McElroy et al., 2010c).
In conclusion, given that the efficacy data are conflicting 
along with concerns about manic/hypomanic switch, the use of 
antidepressant monotherapy is strongly discouraged.
Antipsychotics
Olanzapine. An international trial supported the superiority of 
olanzapine (5–20  mg/d) vs placebo in the treatment of bipolar 
depression. However, olanzapine monotherapy was proven infe-
rior to OFC and furthermore, the analysis of individual MADRS 
items suggested that in contrast with OFC, olanzapine mono-
therapy had no effect on the core symptoms of depression 
(Tohen et al., 2003c). Also, a further small study was underpow-
ered and negative (Amsterdam and Shults, 2005a). Another small 
study was positive (Wang et  al., 2014). It is important to note 
that to demonstrate a true antidepressive effect, an effect on the 
“core items” of depression should be demonstrated (Bech, 2001; 
Lecrubier and Bech, 2007). To answer this question, another trial 
was conducted and the results again suggested that olanzapine 
(5–20 mg/d) was superior to placebo, but again no effect of olan-
zapine was observed on the core depressive symptoms accord-
ing to LOCF analysis but surprisingly MMRM analysis showed a 
significant effect on core symptoms (Tohen et al., 2012). Overall, 
while olanzapine separated from placebo in 2 large clinical trials 
of bipolar depression, the data concerning its efficacy on the core 
symptoms of depression are equivocal.
Quetiapine. Overall, there are 6 studies concerning the efficacy of 
quetiapine in bipolar depression. All of them were positive. Que-
tiapine IR or XR is reported to be efficacious at dosages of both 
300 and 600 mg/d. It is important to note that quetiapine had 
a similar efficacy in BD-I and BD-II patients as well as in rapid 
cycling, and it significantly improved all the MADRS items corre-
sponding to the core symptoms of depression and also improved 
concomitant anxiety (Calabrese et al., 2005b; Thase et al., 2006; 
McElroy et  al., 2010c; Suppes et  al., 2010; Young et  al., 2010; Li 
et al., 2016)
Aripiprazole. Two identically designed, 8-week, multicentre, ran-
domized, double-blind, placebo-controlled studies (CN138-096 
and CN138-146) to evaluate the efficacy and safety of aripiprazole 
monotherapy in depressed BD-I outpatients without psychotic 
features were both negative for aripiprazole (Thase et al., 2008). 
It has been argued that the failure of these 2 trials was due to 
the “catching up” of the placebo group after week 6 rather than 
because of a lack of efficacy of aripiprazole; however, at end-
point the placebo response in terms of MADRS score change in 
the aripiprazole studies (-10.6 and -11.5) was similar to what was 
observed also in the quetiapine studies (from -10.3 to -11.9), while 
the aripiprazole response (-11.9 and -12.3) was clearly lower to the 
response observed with quetiapine (from -15.4 to -17.4). Another 
confounding factor in these studies was that transient use of hyp-
notics was permitted but not after 4 weeks into the trial.
Ziprasidone. There are 2 negative trials (NCT00141271 and 
(NCT00282464) concerning ziprasidone, that were published in 
a single paper (Lombardo et al., 2012). The placebo responses in 
these trials were >50%, that might have contributed to negative 
results. One trial of ziprasidone in bipolar spectrum depressed 
patients was negative (Patkar et al., 2015).
Lurasidone. One 6-week trial in bipolar depressed patients with-
out psychotic features reported that lurasidone (20–60  mg/d or 
80–120 mg/d) was superior to placebo. Lurasidone had an effect 
on the core symptoms of depression. Both lurasidone groups also 
experienced significant improvements compared with placebo in 
anxiety symptoms and in patient-reported measures of quality of 
life and functional impairment (Loebel et al., 2014a). As this was 
a 6-week study, and having in mind the negative findings at end-
point (week 8) for aripiprazole while the data was positive at week 
6, one might be cautious concerning the interpretation of the lur-
asidone data. However, the magnitude of improvement and the 
absolute values of lurasidone and placebo-induced change in the 
MADRS score argue in favor of lurasidone.
Other agents and treatment options. There is a small number 
of early studies on very small samples concerning the α2-
adrenergic agonist clonidine, the α2-adrenergic antagonist idax-
ozan, and Thyrotropin-releasing hormone (Kastin et  al., 1972; 
Jimerson et al., 1980; Osman et al., 1989). A trial concerning the 
usefulness of ECT has been announced (Kessler et al., 2010), but 
its results have not been published until now. Three other uncon-
trolled trials suggested that bipolar depressives respond to ECT, 
and conflicting results exist as to whether unipolar or bipolar 
depression respond better although probably to a lesser extent in 
comparison with unipolars (Daly et al., 2001; Medda et al., 2009; 
Bailine et al., 2010). A  recent study showed ECT to be superior 
to a pharmacotherapy algorithm (Schoeyen et al., 2015). There is 
one negative study of rTMS (Nahas et al., 2003). There is a small 
positive study on the usefulness of cranial electrotherapy stimu-
lation in BD-II depression (McClure et al., 2015).
Comparison of Treatment Options
Since only a limited number of options for the treatment of 
bipolar depression exist, comparison studies are limited and 
often they compare agents with unproven efficacy. Some early 
studies were too small and are problematic concerning their 
methodology (Coppen et al., 1972; Kessell and Holt, 1975; Aberg-
Wistedt, 1982). Overall the comparison data are sparse and they 
suggest antidepressants are equal in efficacy but with a differ-
ent adverse events profile (Baumhackl et al., 1989; Cohn et al., 
1989; Himmelhoch et al., 1991; Grossman et al., 1999; Amsterdam 
and Garcia-Espana, 2000; Silverstone, 2001; Vieta et  al., 2002). 
Clomipramine might be more efficacious than imipramine in 
refractory BD depressed patients (Thase et al., 1992).
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However, the efficacy of antidepressants should be consid-
ered in combination with the negative monotherapy data for 
paroxetine. The frequent use of concomitant mood stabilizers 
as “background” medication complicates the interpretation of 
results. OFC is superior to olanzapine alone (Tohen et al., 2003c) 
and to lamotrigine (Brown et al., 2006) and has an effect on the 
core symptoms of depression. The comparison of paroxetine 
with venlafaxine suggests a higher switching risk for patients 
treated with venlafaxine (Vieta et al., 2002). The relatively higher 
risk of treatment emergent affective switches with venlafaxine 
compared with sertraline or bupropion has also been reported 
(Post et  al., 2006). However, a more recent study reported that 
venlafaxine was equal to lithium and without any increase in 
the switch rate (Lorenzo-Luaces et al., 2016).
Combination and add-on treatment. Combination treatment—
There is one trial in BD-I depressed patients that suggested that 
the OFC (6 and 25, 6 and 50, or 12 and 50 mg/d) was superior both 
to olanzapine monotherapy and to placebo. The OFC arm was rel-
atively small (only 86 patients) and this was one of the limitations 
of the study. The analysis of individual MADRS items suggested 
that OFC had an effect on the core symptoms of depression. In 
comparison with placebo and olanzapine, the OFC arm also had 
a lower number of inpatients, less frequent psychotic features, 
more rapid cycling (that may translate in higher rates of “sponta-
neous remission”), and lower number of centers. All these could 
translate into better response and limit interpretation (Tohen 
et al., 2003c). Another small study was negative but also under-
powered to detect any treatment effect (Amsterdam and Shults, 
2005a). A second study from the United States (STEP-BD) utilized 
a combination treatment by adding paroxetine or bupropion or 
placebo to a mood stabilizer. The results suggested that the 2 anti-
depressant arms did not perform significantly better than placebo 
on top of a mood stabilizer after 26 weeks in terms of recovery 
rates or transient remission. The switch rates were similar as was 
the drop-out rate (Sachs et al., 2007), and neither response to treat-
ment nor switching were dose dependent (Tada et al., 2015). The 
third trial was a 12-week double-blind, randomized, placebo-con-
trolled study from China that reported that carbamazepine plus 
the herbal FEWP (36  g/d) was superior to carbamazepine alone 
and to placebo, but the quality of this study is considered to be low 
because there was no a-priori defined primary outcome (Zhang 
et al., 2007).
In a small study, 21 patients with acute BD-II depression, 
being on therapeutic levels of lithium or valproate, were ran-
domly assigned to treatment with the dopamine D2/D3 antag-
onist pramipexole (n = 10) or placebo (n = 11) for 6 weeks. All 
subjects except for one in each group completed the study. 
There was a superiority of pramipexole in terms of response 
(60% vs 9%; P = .02). One subject on pramipexole and 2 on pla-
cebo developed hypomanic symptoms (Zarate et  al., 2004). 
Another small study randomized 17 BD depressed patients to 
receive adjunctive inositol or placebo for 6 weeks on lithium or 
valproate. The results were numerically in favor of inositol in 
terms of response rates (44% vs 0%; P = .053) (Eden Evins et al., 
2006b).
Add-on treatment—Overall, the data suggest that in bipolar 
depressed patients who experience depression while under 
lithium treatment, it is appropriate to add lamotrigine (van 
der Loos et al., 2009, 2010, 2011), the D2 antagonist L-sulpiride 
(Bocchetta et al., 1993), or maybe oxcarbazepine (Juruena et al., 
2009) but not imipramine (Nemeroff et  al., 2001). The data on 
adding paroxetine and amitriptyline are equivocal (Bocchetta 
et al., 1993; Bauer et al., 1999a; Pilhatsch et al., 2010; van der Loos 
et al., 2010). Imipramine and venlafaxine might pose the patients 
at an increased risk of switching to the opposite pole without any 
visible therapeutic benefit in comparison with other antidepres-
sants (Nemeroff et al., 2001; Vieta et al., 2002)
In BD patients experiencing depression during treatment 
with lithium or valproate, ketamine or lurasidone could be 
added. Lurasidone also improves anxiety and ketamine improves 
suicidality in these patients. Response to a single ketamine infu-
sion appears within minutes but does not last more than 3 to 
4 days (Young et al., 2000; Diazgranados et al., 2010; Zarate et al., 
2012; Loebel et al., 2014b; Xu et al., 2015a). However, there is one 
unpublished failed study with lurasidone as add-on to lithum or 
valproate (Suppes et al., 2013; Sanford and Dhillon, 2015). A small 
placebo-controlled adjunctive study of aripiprazole to lithium 
and citalopram was negative. However, the study was underpow-
ered and the study sample was too small to detect any differ-
ences (Quante et al., 2010).
The data on the options to treat BD patients who experience 
a depressed episode during treatment with mood stabilizers sug-
gest that it is not appropriate to add ziprasidone (Sachs et al., 
2011), and the data are also negative also concerning bipolar 
spectrum depressed patients (Patkar et  al., 2015). The antie-
pileptic agent topiramate and levitiracetam should be avoided 
because there is a risk of worsening depression and inducing 
suicidality (Fountoulakis et al., 2012c, 2015; Siamouli et al., 2014). 
Imipramine and venlafaxine increased the risk of switching to 
the opposite pole without any visible therapeutic benefits in 
comparison with other antidepressants (Sachs et al., 1994, 2011; 
Post et  al., 2001, 2006; Shelton and Stahl, 2004; Schaffer et  al., 
2006; Altshuler et al., 2009; Saricicek et al., 2010).
The data are negative concerning the addition of memantine 
to lamotrigine (Anand et al., 2012) or valproate (Lee et al., 2014a, 
2014b), ketamine to ECT (Abdallah et al., 2012), lisdexamfetamine 
to treatment as usual (McElroy et al., 2015), and the melatoner-
gic antidepressant agomelatine to lithium or valproate (Yatham 
et al., 2016).
Another placebo-controlled study in 85 bipolar depressive 
patients with adjunctive modafinil (a wake-promoting agent; 
mean dose 177 mg/d) demonstrated improved outcomes of bipo-
lar depression without switching to mania or hypomania. Both 
the response and remission rates were significantly higher in 
the modafinil group (44% and 39%) compared with the placebo 
group (23% and 18%) (Frye et al., 2007). Although that study did 
not report a higher risk for manic switches, it has been reported 
that modafinil could cause subclinical switches (Fountoulakis 
et al., 2008c). One published study for the treatment of acute BD-I 
depression with adjunct armodafinil (the longer lasting isomer 
of modafinil; dosage 150 mg/d; n = 128) on lithium, valproate, or 
olanzapine was positive (Calabrese et al., 2010, 2014). However 2 
other studies were reported to be negative (Ostacher, 2014; Ketter 
et al., 2015). One small study on the efficacy of the antidiabetic 
agent pioglitazone as add-on to lithium in bipolar patients with-
out diabetes mellitus was positive (Zeinoddini et al., 2015). A trial 
of celecoxib (400 mg/d) did not support its efficacy as an adjunct in 
the treatment of depressive or mixed episodes (Nery et al., 2008). 
One study with add-on pregnenolone (titrated to 500 mg/d) was 
negative (Brown et al., 2014), while a very small placebo controlled 
trial without an a-priori defined primary outcome suggested that 
adding supraphysiologic doses of levothyroxine (L-T4) to a mood 
stabilizer improves the outcome (Bauer et al., 2016).
Some data support the usefulness of omega-3 fatty acids as 
adjunctive therapy in bipolar depression but not mania, but the 
data are conflicting and inconclusive (Stoll et al., 1999; Chiu et al., 
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2005; Frangou et al., 2006; Keck et al., 2006b; Frangou et al., 2007; 
Murphy et al., 2012; Sarris et al., 2012; Sylvia et al., 2013)
Although there is a wide consensus on the usefulness of 
ECT both against acute mania and acute bipolar depression and 
in refractory cases, controlled hard data are scant (Loo et  al., 
2010). A recent study suggests that ECT may be more effective 
than pharmacotherapy for treatment-resistant bipolar depres-
sion (Schoeyen et al., 2015). Another potential tool could be TMS; 
however, it has been poorly investigated in bipolar depression 
(Dell’Osso et al., 2009). Sleep deprivation and other noninvasive 
circadian-related interventions could be useful add-on treat-
ments to accelerate and sustain the antidepressant response 
(Wu et  al., 2009). One study on bright light therapy in bipolar 
depression was negative (Dauphinais et al., 2012).
Posthoc, Review, and Meta-Analytic Studies
Posthoc analyses of controlled trials. A posthoc analysis of the 
OFC and olanzapine data (Tohen et al., 2003c) reported patients 
with bipolar depression receiving olanzapine or OFC had greater 
improvement in health-related quality of life than those receiv-
ing placebo, and additionally OFC treatment is superior to olan-
zapine alone (Shi et  al., 2004b). A  second posthoc analysis of 
the same data set data reported that the beneficial effect was 
already present at day 7. A number of alternative methods of 
analysis of the data (pattern analysis, survival analysis, and 
mixed-effects regression analysis) confirmed the superior-
ity of both olanzapine and OFC vs placebo (Dube et al., 2007). 
A subanalysis of Japanese subpopulation from the second olan-
zapine study (Tohen et al., 2012) further supported the efficacy 
of olanzapine in the treatment of bipolar depression (Katagiri 
et al., 2013). A pooled analysis of the 2 olanzapine studies (Tohen 
et al., 2003c, 2012) that utilized last observation carried forward 
data supported the efficacy of olanzapine on the core depressive 
items (Tohen et al., 2013).
One posthoc analysis included 2 quetiapine trials (Calabrese 
et al., 2005b; Thase et al., 2006) and confirmed the efficacy of que-
tiapine as monotherapy, in comparison with placebo, for the 
treatment of acute depressive episodes in BD-II disorder (Suppes 
et al., 2008a). Another posthoc analysis of only one of these trials 
(Calabrese et  al., 2005b) concluded that quetiapine significantly 
improved quality of life from week 4 onwards as well as quality of 
sleep (Endicott et al., 2007). A further posthoc analysis of the same 
study reported that the NNT was 5 for both response and remission 
for quetiapine (600 and 300 mg/d) compared with placebo (Cookson 
et al., 2007). Another posthoc analysis of these 2 quetiapine trials 
reported that quetiapine was effective in BD-I depressed patients 
already from week 1 onwards (Weisler et al., 2008).
One posthoc analysis of pooled data from 2 similarly designed 
trials who assessed the impact of aripiprazole monotherapy 
(Thase et  al., 2008) reported that at endpoint aripiprazole was 
not efficacious in the more severely depressed patients (Thase 
et al., 2012). The posthoc analysis of the 2 negative unpublished 
ziprasidone monotherapy trials confirmed that ziprasidone did 
not show superiority over placebo at week 6 in the treatment of 
bipolar depression and was not efficacious in the more or less 
severely depressed patients (Lombardo et al., 2012).
A posthoc analysis of a 6-week trial of imipramine, phenel-
zine or placebo reported that BD-II depressive patients respond 
in a similar way to unipolar patients (Agosti and Stewart, 2007).
An interesting posthoc analysis of the lurasidone stud-
ies developed a mathematical model for the drug and placebo 
responses and trajectories (Chapel et  al., 2016), while a meta-
analysis of combination studies confirmed the higher rate of 
adverse events in comparison with monotherapy (Galling et al., 
2015). A third analysis suggested a beneficial effect of lurasidone 
on functioning that was partially mediated through the improve-
ment of depressive symptoms and partially a direct effect 
(Rajagopalan et al., 2016).
The meta-analysis of ketamine studies support its efficacy 
but suggest the data are conflicting as to whether the therapeu-
tic effect extends beyond day 4 and up to day 7 (Lee et al., 2015; 
Romeo et al., 2015).
Review and meta-analytic studies. A review confirmed that lamo-
trigine had only negative data concerning the primary outcome in 
acute bipolar depression (Amann et al., 2010); however, there was 
some kind of positive signal in some of the secondary outcomes. 
The pooling of raw data from the lamotrigine studies found a sig-
nificant effect in terms of response (HAM-D score, RR = 1.27, 95% CI 
1.09–1.47, P = .002) and remission rates (MADRS score, RR = 1.21, 95% 
CI 1.03–1.42, P = .021). There was a significant change in the MADRS 
total score from baseline (P = .04) but not in the HAM-D (P = .08). 
Baseline severity of depression seemed to play a significant role, 
and lamotrigine was superior to placebo in patients with HAM-D 
score >24 (RR = 1.47, P = .001) but not in those with HAM-D score 
≤24 (RR = 1.07, P = .445). This meta-analysis reported an admixture 
of contradictory results, with lamotrigine being efficacious accord-
ing to one outcome but not according to another (e.g., according 
to MADRS but not to HAM-D and vice versa). Also the interaction 
by severity was because of a higher response rate in the placebo 
group in the moderately ill patients, while the response rate to 
lamotrigine was independent of severity (Geddes et  al., 2009). 
The efficacy of carbamazepine was supported by 2 other reviews 
(Srisurapanont et al., 1995; Yatham et al., 1997).
A number of meta-analyses that were published later 
reported that only quetiapine, OFC, lurasidone, and to a lesser 
extend olanzapine monotherapy exert efficacy in the treatment 
of bipolar depression. They also reported negative results for 
lamotrigine and aripiprazole, lithium as well as for adjunctive 
inositol (Cruz et al., 2010; Kemp et al., 2010; Tamayo et al., 2010; 
Vieta et al., 2010c; De Fruyt et al., 2011, 2012; Gao et al., 2011; Silva 
et al., 2013; Citrome et al., 2014; Mukai et al., 2014; Suttajit et al., 
2014). Also, it was reported that patients who do not respond in 
the first 2 weeks of treatment are unlikely to respond eventually 
and would benefit from a change in treatment (Kemp et al., 2010).
Two meta-analyses using identical studies suggested there 
is some weak efficacy for valproate (Bond et  al., 2010; Smith 
et  al., 2010) and one suggested the same for aripiprazole 
(Fountoulakis et al., 2011a). Another one suggested that treat-
ment with ziprasidone increases the risk for akathisia and 
reported somnolence that seemed to be dose dependent (Gao 
et  al., 2013). There are 3 meta-analysis with conflicting con-
clusions concerning the efficacy of antidepressants (Gijsman 
et  al., 2004; Sidor and Macqueen, 2010, 2012; Vazquez et  al., 
2013) However, it is clear that a class effect is not present con-
cerning antidepressants in bipolar depression (Fountoulakis 
et  al., 2011b). Another meta-analysis suggested that mood 
stabilizer monotherapy is efficacious but the addition of an 
antidepressant does not increase efficacy (Van Lieshout and 
MacQueen, 2010).
One meta-analysis that focused on depressed patients 
with BD-II reported that quetiapine had compelling evidence 
supporting its efficacy, while there was some support for the 
efficacy of lithium, antidepressants, and pramipexole. The 
data for lamotrigine were equivocal (Swartz and Thase, 2011), 
while some data suggest the efficacy of stimulants, especially 
modafinil (Corp et al., 2014), ketamine (Fond et al., 2014; McGirr 
et  al., 2014), and antiinflammatory agents compared with 
Fountoulakis et al. | 135
Copyedited by: oup
conventional therapy alone in the treatment of bipolar depres-
sion (Rosenblat et al., 2016).
Two reviews investigated the issue of the treatment of refrac-
tory bipolar depression and concluded that the available hard 
data are extremely scarce and most of the strategies remain 
essentially experimental; however, there seem to be some that 
are potentially efficacious and promising (Aan Het Rot et  al., 
2012; Sienaert et al., 2013).
One meta-analysis compared the efficacy of ECT in unipo-
lar vs bipolar depression and identified 6 relevant studies. It 
reported a similar rate of response in both disorders (50.9% vs 
53.2%) (Dierckx et al., 2012).
Finally, a meta-analysis reported that the probability of 
receiving placebo, baseline illness severity, and trial duration cor-
relate with placebo response rates and/or clinical trial outcome 
in RCTs of pharmacotherapy for bipolar depression (Nierenberg 
et al., 2015), while another one was negative concerning the use-
fulness of galantamine, donepezil, and memantine (Veronese 
et al., 2016).
Maintenance Treatment
The efficacy data for monotherapy for the maintenance treat-
ment phase are shown in Table 4. The data concerning the com-
bination treatment are shown in Table 5.
Monotherapy
Lithium. There are a number of historic small studies that 
investigated the usefulness of lithium in the maintenance treat-
ment of BD (Baastrup et al., 1970; Melia, 1970; Small et al., 1971; 
Cundall et al., 1972; Hullin et al., 1972; Persson, 1972; Prien et al., 
1973b; Prien et al., 1973a; Dunner et al., 1976; Fieve et al., 1976; 
Fyro and Petterson, 1977; Klein et al., 1981; Christodoulou and 
Lykouras, 1982; Kane et  al., 1982; Margo and McMahon, 1982; 
Mander and Loudon, 1988; Post et al., 1992). All of them reported 
positive findings; however, a number of drawbacks including the 
obsolete methodological approach and the utilization of mixed 
and small samples make the results of these trials difficult to 
interpret.
Overall there are 4 randomized placebo controlled studies 
concerning the efficacy of lithium in the maintenance treatment 
of BD. One is negative/failed (Bowden et al., 2000) and 3 are posi-
tive (Bowden et al., 2003; Calabrese et al., 2003b; Weisler et al., 
2011). The fourth is a small discontinuation study (Kafantaris 
et al., 2004). Two of the positive studies support the usefulness 
of lithium in the prevention of manic but not depressive epi-
sodes irrespective of the polarity of the index episodes (Bowden 
et al., 2003; Calabrese et al., 2003b). The third study also supports 
its usefulness in the prevention of depressive episodes (Weisler 
et al., 2011). There are no data on the efficacy concerning the 
prevention of mixed episodes or for rapid cycling patients. It is 
important to note that the study samples were not enriched for 
response to lithium. On the contrary, one study had a sample 
enriched for response to quetiapine (Weisler et al., 2011), while 
2 others had samples enriched for lamotrigine (Bowden et al., 
2003; Calabrese et al., 2003b), that, however, is not efficacious 
against acute mania. There are some problems with the design 
of the studies, especially concerning the magnitude of improve-
ment during the acute treatment phase and the duration the 
patients were required to be stable before entering the double-
blind phase. With a few exceptions, most are essentially relapse 
prevention, not maintenance studies.
Antiepileptics. Valproate —As mentioned above, there is one 
properly conducted trial (Bowden et al., 2000) in that valproate 
was the agent under investigation. Lithium served as active 
control, and since, as shown above, lithium has proven efficacy 
during the maintenance phase of BD, this specific trial is best 
considered to be a failed study and not negative for valproate.
Carbamazepine—Concerning carbamazepine, there is only one 
small placebo controlled study. Although carbamazepine was 
effective in 60% of cases relative to 22% in the placebo group, 
the differences were not significant likely due to lack of power. 
Further, there were methodological issues with the study design 
and hence, the data are difficult to interpret (Okuma et al., 1981).
Lamotrigine—Overall there are 3 placebo controlled RCTs con-
cerning the efficacy of lamotrigine in the maintenance treat-
ment of BD. Two of them suggest lamotrigine is efficacious in the 
prevention of depressive but not manic episodes irrespective of 
the polarity of the index episodes (Bowden et al., 2003; Calabrese 
et al., 2003b). There are no data concerning index mixed episodes. 
The only study in rapid cycling patients was negative concern-
ing the primary outcome (Calabrese et al., 2000). All studies were 
enriched for tolerability to lamotrigine, but one should keep in 
mind that lamotrigine is neither efficacious against acute mania 
nor acute bipolar depression. There were some problems with the 
design of the studies, particularly concerning the magnitude of 
improvement during the acute treatment phase and the dura-
Table 4. Monotherapy Treatment during the Maintenance Phase, Grading on Basis of Efficacy
Agent/modality
(alphabetical order) Index episode Enriched sample Any episode Manic Depressive
Aripiprazole m* Yes - 1 5
Carbamazepine - - 4 4 4
Fluoxetine d Yes - - 2
Imipramine d ? 5 5 5
Lamotrigine m/d Yes 1 3 1
Lithium m/d No 1 1 3
Olanzapine m Yes/No 1 1 1
Paliperidone m Yes 1 2 5
Quetiapine m/d Yes 2 2 2
Risperidone, LAI m Yes 1 1 5
Valproate m Yes 4 4 3
Abbreviations: -, no data; m, mania/mixed; d, depression; m/d, both mania and depression.
The treatment options are rated according to the rating system shown in Table 1. Enriched sample: the sample is enriched on the basis of remission after treatment 
with the agent under consideration during the acute phase (index episode).
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tion the patients were stable before entering the double-blind 
phase. Essentially they were relapse prevention, not maintenance 
studies.
Antidepressants. There are 2 small, old negative studies con-
cerning the efficacy of imipramine (Prien et  al., 1973a; Kane 
et al., 1982), while on the contrary, 3 other small studies in BD-II 
patients provide some support for the usefulness of fluoxetine 
monotherapy in the prevention of depressive episodes (Amster-
dam et al., 1998; Amsterdam and Shults, 2005b, 2010).
Antipsychotics. Olanzapine—Three trials provide suport for the 
efficacy of olanzapine in the prevention of manic, depressive, or 
mixed episodes in patients with an index manic or mixed episode 
that responded to olanzapine treatment during the acute phase 
(Tohen et al., 2006; Berwaerts et al., 2012a; Vieta et al., 2012). There 
are some data to support the notion that the efficacy of olanzap-
ine is not restricted to those patients who responded to olanzap-
ine during the acute phase. Its long-term effects in rapid cycling 
patients are unknown.
Aripiprazole—There are 2 trials that support the efficacy of 
aripiprazole in the prevention of manic but not depressive epi-
sodes in BD patients after an index manic or mixed episode who 
responded to aripiprazole during the acute phase (Keck et  al., 
2006a; Keck et al., 2007). These 2 trials utilize a methodology that 
satisfies stringent criteria concerning the definition of “mainte-
nance” treatment.
Quetiapine—There is one published positive study that investi-
gated the efficacy and safety of quetiapine IR monotherapy (300–
800 mg/d) as maintenance treatment in BD-I patients compared 
with switching to placebo or lithium. The time to recurrence of 
any mood event was significantly longer for both quetiapine and 
lithium vs placebo. Both quetiapine and lithium significantly 
increased time to recurrence of both manic and depressive epi-
sodes compared with placebo (Weisler et al., 2011). A second study 
in patients who had recovered from bipolar depression reported 
that quetiapine prevented depressive but not manic episodes 
(Young et al., 2014).
Paliperidone—There is one positive study that supports the 
usefulness of paliperidone in the prevention of manic but not 
depressive recurrences in patients with index manic or mixed 
episodes who responded to paliperidone during the acute phase 
(Berwaerts et al., 2012a).
Risperidone long-acting injectable  (RLAI)—Two studies support 
the efficacy of RLAI in the prevention of manic but not depressive 
episodes in BD-I patients with a manic or mixed index episode 
who responded to oral risperidone or RLAI during the acute phase 
(Quiroz et al., 2010; Vieta et al., 2012).
Conclusion of monotherapy trials. Lithium, olanzapine, quetiapine, 
aripiprazole, paliperidone, and RLAI are efficacious in the pre-
vention of manic episodes in patients who recovered from an 
index manic or mixed episode. Olanzapine and quetiapine are 
also efficacious in the prevention of depressive episodes. Que-
tiapine was efficacious irrespective of the index episode. Olan-
zapine was also efficacious in the prevention of mixed episodes. 
There is a lack of data concerning carbamazepine or valproate.
Lamotrigine is efficacious in the prevention of depressive but 
not manic episodes irrespective of index episode. It was not effi-
cacious in the prevention of mixed episodes or in rapid cycling 
patients. The literature does not support the efficacy of imipra-
mine, while, on the contrary, it gives some support for the effi-
cacy of fluoxetine but only in BD-II patients.
All except lithium and olanzapine were proven efficacious 
only in samples enriched for response or tolerability during the 
acute phase. Except from the negative data for lamotrigine there 
are no data concerning rapid cycling patients. Also, except from 
the data concerning olanzapine, there are no data concerning 
Table 5. Combination treatment during the maintenance phase, grading on basis of efficacy.
Overall Manic Depressive
Agent/modality  
(alphabetical order)
Index  
episode
Enriched 
sample MS Lam Li Val MS Lam Li MS Lam Li Val
Aripiprazole m* Yes 2 5 - 5 2 5 - 5 5 - -
CBT D No 2 - - - - - - - - - -
Gabapentin - - - - - - 4 - - - - - -
Imipramine D ? - - 5 - - - - - - -
Lamotrigine m/d Yes - - 4 - - - - - - 5
Lithium m/d No - 4 - - - - - - - - -
Memantine - - - - - 5 - - - - - - -
N-acetyl cysteine D Yes 4 - - - - - - - - - -
Olanzapine M Yes/No 4 - - - - - - - - - -
Oxcarbazepine - - - - 5 - - - 5 - - 5 -
Paroxetine - - 3 - - - - - - 3 - - -
Perphenazine m Yes 5 - - - - - - - - - -
Phenytoin euth No 2 - - - - - - - - - -
Quetiapine m/d Yes 1 - - - 1 - - 1 - - -
Risperidone, long-acting 
injectable
m Yes 2 - - - 2 - - - - - -
Valproate m yes - - - - - - - - 5 - -
Ziprasidone m yes 2 - - - - - - - - - -
Abbreviations: -, no data; CBT, cognitive behavioral therapy; Cbz, carbamazepine; d, depression; Lam: Lamotrigine; Li: Lithium; m, mania/mixed; m/d, both mania and 
depression; MS, mood stabilizer; Val, valproate.
The treatment options are rated according to the rating system shown in Table 1. Enriched sample: the sample is enriched on the basis of remission after treatment 
with the agent under consideration during the acute phase (index episode).
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specifically the prevention of mixed episodes or the response of 
patients with an index mixed episode.
Comparison of Treatments
Lithium vs others.  There are a number of studies comparing lith-
ium with carbamazepine (Placidi et al., 1986; Watkins et al., 1987; 
Lusznat et al., 1988; Stoll et al., 1989; Small et al., 1991; Coxhead 
et al., 1992; Simhandl et al., 1993; Denicoff et al., 1997; Hartong 
et al., 2003) including the MAP study (Greil et al., 1997; Greil and 
Kleindienst, 1999a, 199b; Kleindienst and Greil, 2000, 2002), and 
overall the data suggested that both agents are comparable in 
terms of efficacy. There are some data in favor of a superiority 
of lithium in the treatment of more “classic” patients, but in the 
rest of patients the 2 agents seem to be comparable. Lithium was 
also comparable to valproate in terms of prevention of mood epi-
sodes (Bowden et al., 2000; Calabrese et al., 2005a) and suicidality 
(Oquendo et al., 2011) to olanzapine (Tohen et al., 2005) and also 
to aripiprazole (El-Mallakh et al., 2012)
Furthermore, there was a difference in the clinical profiles of 
lithium and lamotrigine. As mentioned before, 3 placebo-con-
trolled RCTs suggest that lamotrigine was more efficacious in the 
prevention of depressive episodes and lithium in the prevention 
of manic, hypomanic, and mixed episodes (Bowden et al., 2003; 
Calabrese et al., 2003b).
When compared with antidepressants, the available data 
suggest that lithium is superior to imipramine for the preven-
tion of depression in BD-I patients episodes (Prien et al., 1973a; 
Prien et  al., 1984) but inferior to fluoxetine in BD-II patients 
(Amsterdam and Shults, 2010).
A maintenance study reported equal efficacy between ven-
lafaxine and lithium in the prevention of depressive relapses, 
although there was a tendency of better performance for venla-
faxine (Amsterdam et al., 2015)
Antiepileptics vs others.  The studies comparing valproate with 
lithium have already been discussed above (Bowden et al., 2000; 
Calabrese et  al., 2005a; Oquendo et  al., 2011). Two trials sug-
gested valproate is comparable with olanzapine (Tohen et  al., 
2003a) and with a similar cost to healthcare system (Zhu et al., 
2005). Carbamazepine has been studied only in comparison with 
lithium, and these studies have been discussed previously in the 
paragraph concerning lithium (Placidi et al., 1986; Watkins et al., 
1987; Lusznat et al., 1988; Small et al., 1991; Coxhead et al., 1992; 
Simhandl et al., 1993; Denicoff et al., 1997; Greil et al., 1997; Greil 
and Kleindienst, 1999a; Kleindienst and Greil, 2000, 2002; Har-
tong et al., 2003).
Olanzapine vs others. The comparison of olanzapine with lithium 
(Tohen et al., 2005) and valproate (Tohen et al., 2003a; Zhu et al., 
2005) has been discussed above.
One study that constituted the extension of an acute phase 
trial suggested that olanzapine is comparable with asenapine 
(McIntyre et al., 2010a), while another suggested that it is supe-
rior to paliperidone ER (Berwaerts et al., 2012a) and to long-acting 
risperidone (Vieta et al., 2012).
Other comparisons. The comparisons of aripiprazole (El-Mallakh 
et  al., 2012), fluoxetine (Amsterdam and Shults, 2010), imipra-
mine (Prien et al., 1984), and lamotrigine (Bowden et al., 2003; 
Calabrese et  al., 2003b) with lithium, and of asenapine (McIn-
tyre et al., 2010a), paliperidone, and risperidone with olanzapine 
(Berwaerts et al., 2012a; Vieta et al., 2012) have been discussed 
previously.
One 25-week RCT comparing the OFC vs lamotrigine in the 
prevention of bipolar depression reported that bipolar depressive 
patients who responded to OFC do better on long-term OFC in 
comparison with spontaneously improved patients on long-term 
lamotrigine (Brown et al., 2009). The result is difficult to interpret 
as there was an enrichment of the OFC arm, but not the lamo-
trigine arm. Finally, one study compared the efficacy of venla-
faxine in the prevention of bipolar vs unipolar depression and 
reported no difference between groups (Amsterdam and Garcia-
Espana, 2000).
Combination and Add-On Treatment
Combination treatment. There are 3 early studies that investigated 
the combination of lithium with another agent. The lithium plus 
imipramine combination was not more efficacious than lithium 
monotherapy (Kane et  al., 1982; Prien et  al., 1984) and lithium 
or carbamazepine monotherapy was not inferior to their com-
bination that, however, was more efficacious in rapid cycling 
patients (Denicoff et al., 1997). Also the combination of lithium, 
carbamazepine, or valproate with perphenazine was not better 
than mood stabilizer monotherapy; on the contrary, combina-
tion treatment was associated with a shorter time to depressive 
relapse, more drop-outs, and increased rates of dysphoria and 
depressive symptoms (Zarate and Tohen, 2004). Similarly nega-
tive were the results for the lithium or valproate combination 
with olanzapine (Tohen et al., 2004) while, on the contrary, the 
combination with quetiapine had significant advantages irre-
spective of index episode, mood stabilizer and rapid cycling sta-
tus (Vieta et al., 2008a; Suppes et al., 2009). Positive results were 
also reported for their combination with ziprasidone (Bowden 
et al., 2010). Results were negative for aripiprazole plus valproate 
(Woo et al., 2011) or lamotrigine (Carlson et al., 2012).
The OFC was similar to lamotrigine in terms of incidence of 
relapse, but overall bipolar depressive patients who responded to 
OFC do better on long-term OFC in comparison with spontane-
ously improved patients on long-term lamotrigine (Brown et al., 
2009). Lamotrigine plus divalproex was not superior to lamo-
trigine alone concerning the time to depressive episode (Bowden 
et al., 2012).
The open-label BALANCE study results neither reliably con-
firmed nor refuted a benefit of valproate-lithium combination 
therapy compared with lithium monotherapy, but clearly demon-
strated that it is superior to valproate alone (Geddes et al., 2010). 
Another study reported that risperidone or olanzapine adjunctive 
therapy for 24 weeks is beneficial but continuation of risperidone 
beyond this period does not reduce the risk of relapse. Whether 
continuation of olanzapine beyond this period reduces relapse 
risk remains unclear but the potential benefit needs to be weighed 
against an increased risk of weight gain (Yatham et al., 2015).
Overall, there is no compelling data that combination treat-
ment in general does better than monotherapy. Patients sta-
bilized on combination treatment might, however, do worse if 
shifted to monotherapy, and combination treatment with que-
tiapine or ziprasidone plus a mood stabilizer might work better 
than a mood stabilizer alone.
Add-on treatment. A small study supported the adding of pheny-
toin to treatment as usual (Mishory et al., 2003) as did another 
small one for gabapentin (but not on top of antipsychotics) 
(Vieta et  al., 2006). The data are negative for the addition of 
oxcarbazepine (Vieta et al., 2008c) and equivocal for lamotrigine 
(van der Loos et al., 2011) to lithium. Negative data were also 
reported from a trial of adjunctive pramipexole to treatment as 
usual (TAU) in stabilized BD patients with the aim to improve 
neurocognition (Burdick et al., 2011), and from a trial of N-acetyl 
cysteine on TAU in patients after an index episode of bipolar 
depression (Berk et  al., 2012). It is interesting that adjunctive 
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RLAI on TAU significantly prolongs the time to relapse in rapid 
cycling patients (Macfadden et  al., 2009). Adding aripiprazole 
to lithium or valproate also supplied positive results (Marcus 
et al., 2011).
It is reported that patients who respond to treatment with 
lithium, valproate, or carbamazepine plus antidepressants are 
more likely to maintain response with continuation of the com-
bined treatment; however, those patients who manifest only a 
partial acute response are unlikely to further improve when the 
same treatment is continued (Altshuler et al., 2009). Also adjunc-
tive asenapine to lithium or valproate was well tolerated for up 
to 52 weeks, but no efficacy data were reported from that trial 
(Szegedi et al., 2012).
Two trials investigated the efficacy of adjunctive N-acetyl 
cysteine (NAC). The first one randomized 75 BD patients during 
the maintenance phase and reported that NAC treatment caused a 
significant improvement on the MADRS score in comparison with 
placebo (P = .002). Improvements were lost after washout. There 
was no effect of NAC on time to a mood episode and no significant 
between-group differences in adverse events (Berk et al., 2008). The 
second randomized 14 patients (not all of them with high depres-
sion scores) and reported a superiority of the NAC group vs pla-
cebo in terms of remission (P = .031) (Magalhaes et al., 2011b). One 
maintenance study supported the usefulness of ramelteon in the 
prevention of relapse in BD patients (Norris et al., 2013). Negative 
results have been reported for the usefulness of memantine in 
patients on valproate treatment (Lee et al., 2014b).
There are some studies suggesting that there is a role for vari-
ous nutritional supplements such as n-3 fatty acids, chromium, 
choline, magnesium, and tryptophan alone or in combination 
with pharmacotherapies for the treatment of BD, but the data 
are of low quality (Sylvia et al., 2013).
Posthoc, Reviews, and Meta-Analytic Studies
Posthoc analyses. A number of posthoc analyses exist and attempt 
to answer questions that the original papers did not address. 
Posthoc analysis can be informative but can also be a major 
source of publication bias (Vieta, 2007). A  subanalysis of the 
MAP study reported that lithium was superior in classical BD-I 
patients and comparable with carbamazepine in the rest. An 
additional subanalysis including mixed states as an additional 
nonclassical feature confirmed the results (Greil et al., 1998).
Concerning the usefulness of antidepressants, one post-
hoc analysis suggested that the discontinuation rate for any 
reason was lower among patients in the divalproex group tak-
ing a selective serotonin re-uptake inhibitor (SSRI) than among 
patients in the placebo group taking an SSRI (Gyulai et al., 2003b), 
while the application of 4 different remission criteria suggested 
that the application of different definitions of remission does 
not make any significant difference concerning the results (Pae 
et al., 2012). The addition of an atypical antipsychotic-antimanic 
agent in some BD patients might help to reduce suicidal idea-
tion (Houston et al., 2006). Olanzapine might be more beneficial 
if started at an earlier stage of the disease (Ketter et al., 2006), 
and it is also efficacious in patients with an index mixed episode 
(Tohen et al., 2009).
Concerning lithium, it has been reported that only at plasma 
levels between 0.6 and 1.2 mEq/lt it is efficacious in the preven-
tion of both manic and depressive episodes (Nolen and Weisler, 
2013). Another posthoc analysis did not confirm its efficacy in the 
prevention of depressive episodes while it confirmed the efficacy 
of lamotrigine in the prevention of both manic and depressive 
episodes irrespective of index episode (Calabrese et  al., 2003a; 
Goodwin et  al., 2004). These results still held true when early 
relapses that occurred in the first 90 or 180 days were excluded 
from the analysis (Calabrese et  al., 2006). The lack of efficacy 
of lithium in a subgroup of patients might be due to lithium 
induced thyroid function abnormalities in a subpopulation of 
patients (Frye et  al., 2009). Overall, lamotrigine performed bet-
ter in comparison with lithium in terms of remission and the 
persistence of subsyndromal symptoms (Frye et al., 2006). Some 
positive results for NAC were also suggested by 2 posthoc analy-
sis (Magalhaes et al., 2011a, 2013).
Review and meta-analyses. One review confirmed the efficacy 
of lithium but reported that there is no definitive evidence as to 
whether or not lithium has an anti-suicidal effect (Burgess et al., 
2001). A  more recent meta-analysis confirmed the antisuicidal 
effect of lithium vs placebo but not its superiority over other agents 
except carbamazepine (Cipriani et al., 2013). Two other studies sup-
port the usefulness of RLAI (Bobo and Shelton, 2010) and of ziprasi-
done for the maintenance treatment of BD-I disorder in adults as 
an adjunct to lithium or valproate (Citrome, 2010). Another review 
identified 4 issues that limit the interpretation of trials (insufficient 
duration, enriched sample, possible conflation with iatrogenic 
adverse effects by abrupt medication discontinuation with benefi-
cial effects on treatment, and a low overall completion rate) (Tsai 
et al., 2011).
Concerning meta-analysis, the first one for carbamazepine 
failed to prove the prophylactic efficacy (Dardennes et al., 1995). 
A second one concluded that the data for oxcarbazepine are of 
very low quality not allowing firm conclusions (Vasudev et al., 
2008). A fair number of meta-analyses focused on lithium. One 
confirmed its efficacy but failed to find sufficient evidence to 
prove that a lithium-withdrawal relapse phenomenon exists, 
that is patients relapse soon after stopping lithium and the 
symptomatology turns refractory to treatment (Davis et  al., 
1999). Another one supported an antisuicidal efficacy of lithium 
(Tondo et al., 2001). Three others confirmed the prophylactic anti-
manic efficacy of lithium but were equivocal for the prophylactic 
efficacy against depressive episodes (Burgess et al., 2001; Geddes 
et al., 2004; Severus et al., 2014).
Furthermore, a number of meta-analytic studies confirmed 
the prophylactic antimanic efficacy of specific agents and the 
antidepressant of others. It is important to mention that among 
other more or less expected results, the antidepressant efficacy 
of valproate and imipramine was supported (Beynon et al., 2009) 
as well as of lithium (Popovic et al., 2010), while the prophylactic 
antidepressant efficacy of olanzapine was questioned (Cipriani 
et  al., 2010). Antipsychotics might be superior to lithium and 
anticonvulsants but with more adverse effects (Vazquez et  al., 
2015a, 2015b).
The issue of combination treatment has been the focus of 
2 meta-analyses. They both reported negative conclusions for 
the addition of antidepressants (Ghaemi et al., 2008; Beynon 
et al., 2009). A third analysis suggested that no monotherapy 
was associated with a significantly reduced risk for both 
manic/mixed and depressive relapse, and only quetiapine 
plus lithium or divalproex was associated with a significantly 
reduced risk for relapse towards both the manic/mixed and 
depressive pole (Vieta et  al., 2011). This specific meta-anal-
ysis also pointed out that the majority of studies included 
samples enriched for response to a specific agent during the 
acute phase.
Finally, pharmaco-epidemiological data suggest that val-
proate and lithium might have a protective effect against any 
psychiatric hospitalization for patients with BD in a real world 
setting, while lamotrigine and carbamazepine might exert 
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protective effects solely against depressive and manic episodes, 
respectively (Joas et al., 2015).
Treatment of Mixed Episodes
Mixed episodes are no longer accepted as a diagnostic entity by 
DSM-5; instead “mixed features” is included as a specifier and this 
creates a degree of confusion for future treatment recommen-
dations, since the 2 concepts differ significantly (Fountoulakis, 
2015d). So far, mixed episodes have been combined with pure 
manic episodes in RCTs and results have been reported together. 
Only a few papers, usually posthoc analyses, report the results 
concerning mixed episodes separately. Unfortunately all data on 
mixed episodes stem from trials of acute mania and only one trial 
reports on the efficacy of lurasidone in bipolar depressive patients 
with mixed features. That trial supported the efficacy of lurasi-
done in these patients for the improvement of both depressive 
and manic symptoms (McIntyre et al., 2015; Suppes et al., 2015). 
Another important limitation is that the results reported usually 
concern only the manic but not the depressive component of the 
mixed episode (Fountoulakis et al., 2012b). The ranking of the data 
for the treatment of mixed episodes is shown in Table 6.
Treatment of Acute Mixed Episodes
Aripiprazole and carbamazepine were found efficacious in the 
treatment of both the manic and the depressive component of 
acute mixed episodes (Keck et  al., 2003b; Weisler et  al., 2004, 
2005, 2006; Sachs et al., 2006; Suppes et al., 2008b). Ziprasidone 
was also found to be efficacious against both components, but 
the definition of mixed states was different from the DSM.
Olanzapine and valproate were reported to be efficacious 
against mania but the data are inconclusive concerning the 
depressive component (Tohen et al., 1999, 2000; Baker et al., 2003; 
Baldessarini et  al., 2003b; Shi et  al., 2004a; Bowden et  al., 2006; 
Ghaemi et al., 2007; McIntyre et al., 2009b). The posthoc analysis of 
the 2 bipolar depressive trials suggested that olanzapine was effi-
cacious in those patients with mixed features suggesting an effect 
also on the depressive component (Tohen et al., 2014). Furthermore, 
risperidone but not asenapine is reported to be efficacious against 
the manic component, but no data exist concerning their efficacy 
on the depressive component (Khanna et al., 2005; McIntyre et al., 
2009b). A posthoc analysis suggested that asenapine but not olan-
zapine improved the quality of life in mixed patients (Michalak 
et al., 2014), and another 2 suggested that asenapine improved both 
the manic and depressive component in comparison with placebo 
and was also found superior to olanzapine concerning the manic 
but not the depressive component (McIntyre et al., 2013; Berk et al., 
2015). However, a more recent trial was negative (Landbloom et al., 
2016). Paliperidone was efficacious only against the manic com-
ponent (Vieta et al., 2010c; Berwaerts et al., 2012b). One study for 
quetiapine was a failed one (Cutler et al., 2011).
The combination of olanzapine olanzapine plus lithium 
or valproate have positive data concerning both components 
(Tohen et al., 2002b; Baker et al., 2004; Houston et al., 2006, 2009, 
2011). In mixed depression the OFC was comparable with olan-
zapine and both were superior to placebo, but due to the small 
number of subjects the report does not permit to derive conclu-
sions (Tohen et al., 2003c; Benazzi et al., 2009). The data concern-
ing the combination of haloperidol or risperidone plus lithium 
or valproate were negative (Sachs et al., 2002). Overall it seems 
that second generation antipsychotics (SGAs) are effective in 
treating acute mixed episodes of BD, with predominant manic 
symptoms. Their efficacy in treating depressed mixed episodes 
remains unclear (Muralidharan et al., 2013).
The only trial in patients in bipolar depressive episode with 
mixed features supported the efficacy of lurasidone in these 
patients for the improvement of both depressive and manic 
symptoms (McIntyre et al., 2015; Suppes et al., 2015).
Maintenance Treatment of Mixed Bipolar Episodes
The data so far suggest that olanzapine prolongs time to relapse 
into any episode in patients with an index mixed episode (Tohen 
et al., 2006, 2009) while on the contrary, lithium and valproate 
had negative results in patients with a dysphoric manic index 
episode (Bowden et al., 2005a). Additionally, the data are in sup-
port of the combination of quetiapine plus lithium or valproate 
(Vieta et  al., 2008a; Suppes et  al., 2009) but are negative con-
cerning aripiprazole in patients with an index mixed episode 
(Yatham et al., 2013a).
Table 6. Treatment of Mixed Episodes
 Acute Phase Maintenance Phase
Monotherapy Combination with MS
 Monotherapy
Combination
Agent/modality
(alphabetical order)
Manic  
component
Depressive
component
Manic
component
Depressive
component MS Cbz Lam Li Val
Aripiprazole 3 3 - - - 2 - 5 - -
Asenapine 4 4 - - - - - - - -
Carbamazepine 3 3 - - - - - - - -
Celecoxib - - 5 5 - - - - - -
Haloperidol - - 5 5 - - - - - -
Lithium 5 - - - - - - - - -
OFC 4 4 - - - - - - - -
Olanzapine 3 3 2 2 1 - - - - -
Paliperidone 3 5 - - - - - - - -
Quetiapine 5 - - - - - - - - -
Risperidone 3 - 5 5 - - - - - -
Valproate 3 4 - - - - - - - -
Ziprasidone 4 4 - - - - - - - -
Abbreviations: -, no data; Cbz, carbamazepine; Lam, lamotrigine; Li, lithium; MS, mood stabilizer; OFC, olanzapine-fluoxetine combination; Val, valproate.
The treatment options are rated on the basis of efficacy according to the rating system shown in Table 1.
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Treatment of Rapid Cycling Patients
The treatment of rapid cycling patients constitutes a challenge. 
Often their course frustrates the therapist and the evaluation of 
treatment is difficult because of the rapid switching from one 
pole to another (Fountoulakis et  al., 2013). The ranking of the 
treatment of rapid cycling patients is shown in Table 7.
Treatment of Acute Episodes in Rapid Cycling Patients
Olanzapine is effective in reducing symptoms of mania and was 
well tolerated in rapid cycling BD-I patients as shown by a sec-
ondary analysis (Sanger et al., 2003). The pooling of data from 2 
RCTs reported that improvement of mania with olanzapine was 
similar in rapid cyclers and non-rapid cyclers. However, rapid 
cyclers showed an earlier response (Vieta et al., 2004). One trial 
was also positive concerning aripiprazole in acutely manic rapid 
cycling patients (Sachs et al., 2006).
Although one study on acute mania in rapid cycling patients 
was a failed one (Cutler et al., 2011), one a priori planned suba-
nalysis of data from rapid cycling patients with acute BD-I or 
BD-II depression suggested that quetiapine monotherapy (300–
600  mg/d) was effective and well tolerated (Vieta et  al., 2007). 
The posthoc analysis of the rapid cycling subsample of bipolar 
depressives from the BOLDER study confirmed this (Cookson 
et al., 2007), and finally the subanalysis of the data from a small 
number of depressed rapid cycling BD patients again suggested 
that 300 mg of quetiapine monotherapy was superior to placebo 
(Suppes et al., 2010).
It seems that lithium has a week but positive effect (Young 
et al., 2010) and also there are some positive but equivocal data 
for valproate (Muzina et al., 2010). On the other hand, the data 
are clearly negative for paroxetine (McElroy et al., 2010c).
The combination of lithium and divalproex was not effective 
and the further addition of lamotrigine did not seem to add any-
thing in Terms of efficacy (Kemp et al., 2012b)
Relapse Prevention in Rapid Cycling Patients
For the prevention phase, the data so far suggest that dival-
proex is not more effective than lithium (Calabrese et al., 2005a) 
and also that the combination of lithium plus divalproex is not 
better than lithium alone (Kemp et al., 2009). One small study 
reported that the combination of lithium plus carbamazepine 
did better than either agent alone (Denicoff et al., 1997). It is 
interesting that the data are negative for lamotrigine, although 
in some secondary outcomes there was a beneficial signal 
especially in BD-II patients (Calabrese et al., 2000). Overall, the 
widely believed concept among clinicians that divalproex is 
more effective than lithium in the long-term management of 
rapid-cycling BD was not supported by a trial on 139 patients 
(Findling et al., 2005).
One posthoc analysis suggested that aripiprazole was effi-
cacious (Muzina et al., 2008). There are no data on other antip-
sychotics in monotherapy concerning the maintenance phase. 
A posthoc analysis reported that rapid cycling patients did less 
well during the extended observation period than nonrapid 
cycling patients, regardless of treatment and that overall olan-
zapine and divalproex appeared comparable (Suppes et al., 2005).
Another study confirmed the efficacy and safety of quetia-
pine add-on to lithium or divalproex in the prevention of mood 
episodes in rapid cycling BD-I patients with most recent episode 
manic/mixed or depressive (Vieta et  al., 2008a). There was a 
North American study with a similar design as the previous one 
reporting similar results (Suppes et al., 2009). A large controlled 
trial that evaluated adjunctive maintenance treatment with 
RLAI on TAU in 240 BD-I patients with at least 4 mood episodes 
in the 12  months prior to study entry yielded positive results 
(Macfadden et al., 2009).
The results of the STEP-BD support a role of antidepressants 
in the development of rapid cycling in a subpopulation of BD 
patients (Schneck et al., 2008; Ghaemi et al., 2010). A similar con-
clusion came from earlier randomized controlled study of rapid 
cycling patients using a double-blind on-off-on-off design with 
the use of tricyclic antidepressants (Wehr et al., 1988)
Finally, the data are negative concerning the administration 
of 6  g/d of ethyl-eicosapentanoate as augmentation of treat-
ment with mood stabilizers in rapid cycling patients with bipolar 
depression (Keck et al., 2006b).
One meta-analysis suggested that lithium is at least par-
tially efficacious in rapid cycling patients (Kupka et al., 2003), 
another one suggested there is no clear advantage of any treat-
ment option vs the others (Tondo et  al., 2003), while a third 
one proposed that some atypical antipsychotics (especially 
quetiapine and olanzapine) may be considered as the first-line 
treatment options (Cruz et al., 2010). The meta-analysis of 20 
studies published from 1974 to 2002 comparing subjects with 
rapid and nonrapid cycling BD reported that in contrast to 
common beliefs, lithium prophylaxis has at least partial effi-
cacy in a considerable number of rapid cyclers, especially when 
antidepressants are avoided. Hypothyroidism may be associ-
ated with mood destabilization in vulnerable patients (Kupka 
et al., 2003).
Treatment of Special Conditions
Treatment of Comorbid Conditions
Comorbidities are common in bipolar patients and often need 
more elaborated therapeutic interventions (Fountoulakis, 2015e, 
2015f, 2015g).
Treatment of comorbid substance abuse disorder  (SUD). There are 
2 placebo controlled trials suggesting that the combination of 
valproate and lithium in BD patients with co-occurring alcohol 
dependence improves both mood and alcohol use symptoms (Sal-
loum et al., 2005, 2007) and that lithium treatment in BD adoles-
cents improves mood and substance use symptoms (Cerullo and 
Strakowski, 2007). Lithium can be used for the treatment of con-
comitant substance and polysubstance abuse (Geller et al., 1992, 
1998), and quetiapine and risperidone can reduce drug craving 
Table  7. Treatment of Rapid Cycling Patients during the Different 
Phases of BD
Agent/modality  
(alphabetical order)
ACUTE 
mania Depression Maintenance
Aripiprazole 3 - 3
Carbamazepine - - 2 (Li + Cbz)
Lamotrigine - - 5
Lithium 4 3 2 (Li, Li + Cbz)
Olanzapine 3 - -
Paroxetine - 5 -
Quetiapine 3 2 2 (Quet+ Val/Li)
Risperidone, long-acting 
injectable
- - 2 (RLAI+TAU)
Valproate 4 4 -
Abbreviations: -, no data; Cbz, carbamazepine; Li, lithium; Quet, quetiapine; 
RLAI, risperidone long-acting injectable; TAU, treatment as usual; Val, valproate.
The treatment options are rated on the basis of efficacy according to the rating 
system shown in Table 1.
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(Nejtek et al., 2008). On the contrary, the data concerning quetia-
pine for alcohol abuse are negative (Brown et al., 2008; Sherwood 
Brown et al., 2014). For bipolar patients with alcohol dependence, 
the opiate receptor antagonist naltrexone could be useful (Sher-
wood Brown et al., 2009), and a preliminary report is positive for 
acamprosate (Tolliver et  al., 2012) but negative concerning the 
treatment of any substance use with NAC (Bernardo et al., 2009). 
One trial on the usefulness of citicoline in the treatment of cocaine 
use was inconclusive (Brown et al., 2015) as was one study with 
the use of topiramate in alcohol dependence (Sylvia et al., 2016).
There are open-label medication trials that provide limited 
support to quetiapine, aripiprazole, bupropion, and lamotrigine 
for the treatment of BD patients with cocaine dependence. Also, 
aripiprazole might be helpful in patients with alcohol use disor-
ders (Cerullo and Strakowski, 2007; Sepede et al., 2014).
Overall, while some data are available for alcohol, cannabis, 
and cocaine use comorbid with BD, the evidence is sparse con-
cerning heroin, amphetamine, methamphetamine, and polysub-
stance SUD comorbid with BD (Beaulieu et al., 2012).
Treatment of comorbid anxiety and disorders. A posthoc analysis of 
anxiety symptoms with data from 2 RCTs of 8-week duration of 
quetiapine (300 or 600 mg/d) (Calabrese et al., 2005b; Thase et al., 
2006) reported that at endpoint there was no difference between 
treatment groups and placebo concerning the total HAM-A 
score, but there was a difference both for the psychic and the 
somatic anxiety subscale scores in comparison with placebo 
(P < .001) (Lydiard et al., 2009). Also, quetiapine XR (50–300 mg/d) 
was superior both to divalproex ER (500–3000 mg/d) and placebo 
in the improvement of anxiety in BD patients with comorbid 
panic attacks or generalized anxiety disorder (GAD) (Sheehan 
et al., 2013). In another study, again quetiapine (300 or 600 mg/d) 
and paroxetine (20 mg/d) produced a significant improvement 
in anxiety in terms of change of HAM-A scale score from base-
line in acutely depressed BD patients (McElroy et al., 2010c). Of 
note, quetiapine (300–600 mg/d) also significantly improved the 
HAM-D score from baseline, while this was not the case with 
paroxetine (600–1800  mg/d; P = .279) (Young et  al., 2010). How-
ever, another study was negative for quetiapine concerning its 
effect on depression in BD patients with GAD (Gao et al., 2014).
Lurasidone (20–60 mg/d; n = 166 or 80–120 mg/d) also signifi-
cantly improved anxiety symptoms in comparison with placebo 
(Loebel et al., 2014a). On the contrary, risperidone monotherapy 
was not an effective anxiolytic for BD patients with comor-
bid panic disorder or GAD in doses of 0.5–4 mg/d over 8 weeks 
of treatment (Sheehan et  al., 2009), and similar results were 
obtained with ziprasidone (Suppes et al., 2014).
The data concerning divalproex (rapidly titrated up to 2500 mg/d, 
as tolerated, to a target serum level of 50–100 mg/dL) are equivocal, 
because the only positive study was based on a very small study 
sample (25 outpatients with BD-I depression) (Davis et al., 2005).
It is reasonable to suggest that also benzodiazepines can be 
used as adjunctive medication for sedation or for the treatment 
of anxiety, although abuse, tolerance, and dependence consti-
tute important problems. Although approved for the treatment 
of GAD, pregabalin has no data in BD. However, again it is rea-
sonable to suggest it might be a useful agent for the treatment 
of anxiety disorders that commonly accompany BD and could 
substitute for benzodiazepines. A significant advantage is that it 
is not metabolized by the liver.
There is one study suggesting that adjunctive topiramate 
could be beneficial in the treatment of BD with comorbid obses-
sive compulsive disorder, but the overall design and reporting of 
results does not permit reliable conclusions (Sahraian et al., 2014).
The ranking of the treatment of comorbid anxiety is shown 
in Table 3.
Weight  gain. Topiramate is not effective in the treatment of 
BD per se; however, it is unique because of its ability to cause 
weight loss at dosages of 50 to 200 mg/d. A review reported that 
more than 70% of patients taking topiramate for a mean dura-
tion of 5 months lost a mean of 5 to 6 kilograms (Arnone, 2005). 
However, topiramate might cause de novo depression and suici-
dality in some patients, although no completed suicides related 
to topiramate have been reported (Fountoulakis et al., 2012c).
Treatment of agitation. Probably most clinicians would choose 
antipsychotics in severely agitated bipolar patients, and this 
option is supported by a double blind clinical trial that reported 
that intramuscular haloperidol (5–10 mg) was equal in efficacy 
but faster acting in comparison with intramuscular clon-
azepam (1–2  mg) in agitated mania at 0, 30, and 60 minutes 
(Chouinard et al., 1993). Similarly, i.m. olanzapine (10 mg, first 
2 injections; 5 mg, third injection) was reported to be superior 
to lorazepam (2 mg, first 2 injections; 1 mg, third injection) for 
the control of agitation in manic patients. Already 2 hours after 
the first injection, patients treated with olanzapine showed a 
significantly greater reduction in scores on all agitation scales 
compared with patients treated with either placebo or loraz-
epam (Meehan et al., 2001).
Valproate oral loading of 20 mg/kg/d was reported to be com-
parable with haloperidol 0.2 mg/kg/d for the treatment of exited 
manic patients in a single blind study and the effect was evident 
within 3  days from starting (McElroy et  al., 1996). Overall, val-
proate loading up to 30 mg/kg/d was reported to be safe and well 
tolerated (Hirschfeld et al., 1999).
Inhaled loxapine exerted an antiagitation effect at 10 min-
utes at both the 5- and 10-mg doses and was superior to pla-
cebo at all time points measured. For safety reasons it has 
been recommended that inhaled loxapine should be restricted 
to a single dose in 24 hours and needs to be subject to a Risk 
Evaluation and Mitigation Strategy program (Citrome, 2012; 
Kwentus et al., 2012). In Europe, 2 doses are allowed (the sec-
ond must be given 2 hours after the initial inhalation) (Popovic 
et al., 2015).
The issue of agitation with aripiprazole is controversial. As 
an adverse event it is not reported in the dataset and on the con-
trary, aripiprazole is a recommended evidence based treatment 
against agitation associated with schizophrenia or bipolar mania 
(Sanford and Scott, 2008; Gonzalez et  al., 2013; Citrome et  al., 
2016). However, it has been reported under naturalistic condi-
tions (Di Lorenzo et al., 2007) and especially in vulnerable popu-
lations such as elderly patients (Coley et al., 2009). Agitation has 
also been described when initiating aripiprazole in patients after 
prolonged treatment with potent D2 blocking agents that may 
result in an upregulation of postsynaptic dopamine receptors 
(Lea et al., 2007). However, a major obstacle for a fair estimate of 
the rate of agitation with aripiprazole is that akathisia can easily 
be mistaken as agitation (Thomas et al., 2015), especially by less 
experienced raters.
Treatment of Neurocognitive Deficits
The presence of a significant neurocognitive deficit in BD patients 
has been solidly shown and it concerns all phases of the disorder, 
including periods of euthymia (Tsitsipa and Fountoulakis, 2015). 
Galantamine may have specific benefits for episodic memory, but 
not processing speed, in patients with cognitive impairment as part 
of BD (Ghaemi et al., 2009). One study reported that pramipexole 
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may improve neurocognition in euthymic patients only (Burdick 
et al., 2012) while the data are negative for NAC (Dean et al., 2012).
Adjunctive intranasal insulin (40 IU q.i.d.; n = 34) had a ben-
eficial effect on executive function but not on the other neu-
rocognitive measures in euthymic patients (McIntyre et  al., 
2012a). Also adjunctive mifepristone, which is a synthetic 
steroid, at 600 mg/d improved spatial working memory in BD 
depressed patients, and this was evident also 7 weeks after the 
cessation of treatment (Watson et al., 2012)
ECT was reported to produce an improvement in neurocogni-
tive function similar to that of algorithm-based pharmacological 
treatment (Kessler et al., 2014).
Suicide
There is much discussion concerning the potential antisuicidal 
efficacy of specific drugs and especially of lithium. However, 
almost all the data come from studies of naturalistic and epide-
miological nature and no controlled studies exist.
There is only one posthoc analysis that investigated suici-
dality in BD-I patients during treatment with olanzapine in 
combination with lithium or divalproex. In mixed patients 
with residual suicidality, suicidal thoughts were associated 
with somatic discomfort, agitated depression, and psychosis. It 
seems that combination therapy with olanzapine plus lithium 
(n = 36) vs lithium alone (n = 22) significanlty reduced the score 
in the suicidal item of the HAM-D by 58% vs 29% (P < .05) within 
1 week and all associated symptoms within 2 weeks by aver-
ages of 31% vs 12% (P < .05) (Houston et al., 2006). The analysis 
of pharmaco-epidemiological data suggests that treatment with 
lithium but not with valproate is associated with lower suicidal-
ity (Goodwin et al., 2003; Song et al., 2015).
Nonbiological Treatment Options
There are some but overall limited data concerning the usefulness 
of specific adjunctive psychotherapies (Reinares et al., 2014; Miziou 
et al., 2015). Research so far has focused on acute depression and 
the maintenance phase but not on acute mania. These studies suf-
fer from the same limitations and methodological problems as all 
psychotherapy trials do. There is no universally accepted standard-
ized method to conduct this kind of study and blinding and the 
nature of the control intervention are unresolved limitations. The 
grading of these treatment options is shown in Table 8.
Cognitive-Behavioral Therapy (CBT)
The overall data for the long-term efficacy of CBT either as mono-
therapy or as add on to psychoeducation and in comparison with 
TAU are negative concerning relapse prevention. However, there 
are some positive results for the acute depressive phase in BD 
(Ball et al., 2006; Scott et al., 2006; Zaretsky et al., 2008; Costa et al., 
2011; Gomes et al., 2011; Meyer and Hautzinger, 2012; Gonzalez 
Isasi et al., 2014). A posthoc analysis suggested that CBT could be 
more effective than TAU in patients with <12 previous episodes, 
but less effective in those with more episodes (Scott et al., 2006). 
In BD patiens with insomnia, CBT for insomnia was superior to 
psychoeducation concerning manic relapses (Harvey et al., 2015).
Psychoeducation
The data on adjunctive psychoeducation suggest that in compari-
son with TAU or nonspecific intervention, it prevents relapse to 
both poles if administered to patients in clinical remission (Perry 
et al., 1999; Colom et al., 2003, 2009; Lobban et al., 2010; de Barros 
et al., 2013) but it has no effect on biological rhythms (Cardoso 
Tde et al., 2015). Again a posthoc analysis suggested that patients 
with more than 7 episodes did not show significant improvement 
with group psychoeducation for time to recurrence, and those 
with more than 14 episodes did not benefit from the treatment 
in terms of time spent ill (Colom et al., 2010). A systematic review 
confirmed the above (Bond and Anderson, 2015).
Interpersonal and Social Rhythm Therapy (IPSRT)
Overall there are no convincing data on the usefulness of IPSRT 
during the maintenance phase of BD; however, there are some 
data suggesting that if applied early and particularly already 
during the acute phase, it might prolong the time to relapse 
(Frank et al., 2005, 2008; Swartz et al., 2012; Inder et al., 2015).
Family Focus Treatment
Overall the literature supports the idea that interventions 
that focus on families and caregivers exert a beneficial impact 
especially on family members, but the effect on the patients 
themselves is controversial and uncontrolled. Probably it 
improves issues like treatment adherence and family dynamics 
(Miklowitz et al., 2000, 2003; Rea et al., 2003; Reinares et al., 2004, 
2008; D’Souza et al., 2010)
Intensive Psychosocial Intervention
“Intensive” psychotherapy is another option but it is of unknown 
efficacy with limited research support (Miklowitz et al., 2007a, 
2007b). The term refers to up to 30 sessions of CBT, IPSRT, or fam-
ily focus treatment within 9 months.
Cognitive Remediation and Functional Remediation
The data are positive in improving functioning, that is the critical 
endpoint, but mostly negative concerning cognitive outcomes 
Table 8. Grading of the Evidence for the Efficacy of Nonbiological Treatment Options
Intervention
Efficacy
Relapse/
recurrence Manic symptoms Depressive symptoms Anxiety Neurocognition Overall functioning
CBT 5 - 3 - - -
Psychoeducation 3 5 5 - - 3
IPSRT 4 - - - - -
Family intervention 5 5 5 - - 5
Intensive psychosocial 
intervention
- - - - - -
Cognitive remediation 5 5 5 - 5 5
Mindfulness based interventions 5 5 5 3 - -
Abbreviations: -, no data; CBT, cognitive behavioral treatment; IPSRT, InterPersonal and Social Rhythms Therapy.
The treatment options are rated according to the rating system shown in Table 1.
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when using cognitive remediation techniques as add on to TAU 
in BD patients (Martinez-Aran et  al., 2011; Lahera et  al., 2013; 
Torrent et  al., 2013), although a more recent posthoc analysis 
was promising (Sole et al., 2014).
Mindfulness-Based Interventions (MBCT)
Overall the data do not support a beneficial effect of MBCT on 
the core symptoms of BD but also suggest that MBCT could be 
useful in the reduction of anxiety in BD patients. So far there 
are no data supporting its efficacy in the prevention of recur-
rences (Williams et  al., 2008; Ives-Deliperi et  al., 2013; Perich 
et al., 2013a, 2013b).
Internet-Based Interventions
There is only one randomized trial that compared a completely 
Internet-based preventive program for BD, adjunctive to usual 
pharmacological management vs a control intervention. The 
results suggested no differences between treatment groups 
(Barnes et al., 2015). The design of the study precludes deriving 
general conclusions for the efficacy of web-based approaches. 
Another study that combined psychoeducation with mobile 
phone technology did not show any benefit vs paper and pencil 
method, however this could mean that a mobile phone approach 
could be an important alternative without compromising the 
outcome (Depp et al., 2015).
Safety Issues With Pharmacotherapy of BD
A comprehensive grading of all agents in terms of their safety 
and tolerability profile is shown in Table 9.
Lithium
Lithium has a narrow therapeutic window concerning its 
dosage and plasma levels (recommended plasma level 0.6–
1.2  mmol/L), and laboratory testing and thorough inves-
tigation before starting lithium treatment (ECG; kidney 
function etc.) is necessary. Unfortunately this often delays 
the initiation of treatment. Adverse events are more fre-
quent with higher doses, while “rebound mania” has been 
described upon withdrawal. The most frequent adverse 
events include neurological, endocrinological (more often 
from the thyroid), cardiovascular, renal, gastrointesti-
nal, hematological, and dermatological manifestations, 
and lithium intoxication is not rare. In clinical practice 
patients often complain of sedation and tremor and some-
times a decline in creative thinking (Shaw et  al., 1986; 
Engelsmann et  al., 1988; Stoll et  al., 1996). A  general nega-
tive impact of lithium on neurocognitive function has been 
reported (Karniol et al., 1978; Kropf and Muller-Oerlinghausen, 
1979; Reus et al., 1979; Squire et al., 1980; Connelly et al., 1982; 
Lund et al., 1982; Shaw et al., 1987; Engelsmann et al., 1988; 
Maarbjerg et al., 1988; Kocsis et al., 1993; Kessing, 1998; Honig 
et  al., 1999; Bora et  al., 2007; Senturk et  al., 2007; Goldberg, 
2008). It seems that there is a complex relationship between 
lithium treatment, female gender, hypothyroidism, and rapid 
cycling (Cowdry et al., 1983; Bauer and Whybrow, 1990; Bauer 
et  al., 1990; Gyulai et  al., 2003a; Fountoulakis et  al., 2008b). 
While most authors argue that lithium is neuroprotective, a 
neurotoxic effect is also possible in the long term, even at 
therapeutic levels, especially in combination with antipsy-
chotics (Fountoulakis et  al., 2008b). Comprehensive guide-
lines concerning lithium treatment and optimal therapeutic 
serum levels are available and should be applied (Malhi et al., 
2011), and a recent review provides up-to-date information 
on its safety (Murru et al., 2015).
Antiepileptics
The recommended therapeutic valproate serum concentration is 
50 to 150 mg/mL. It is not recommended to be used in women 
of childbearing age because of the high frequency of unplanned 
pregnancies in bipolar females and the relatively high terato-
genicity of valproate. Other potential acute side effects are weight 
gain and hair loss. Its use has been associated with polycystic 
ovary syndrome (PCOS). It is to be noted however, that similar to 
epilepsy, there is an association between PCOS and major psychi-
atric disorders, including BD. An increased risk can also be dem-
onstrated in their siblings suggestive of shared familial factors 
between PCOS and psychiatric disorders (Cesta et al., 2016).
The typical dosage of carbamazepine in the treatment of 
acute mania is 600 to 1800 mg/d (serum concentration 4–12 mg/
mL). After several weeks under carbamazepine, an induction of 
hepatic enzymes (CYP 3A4) occurs and the drug levels drop and 
may require additional upward dose titration (Bertilsson and 
Tomson, 1986). The dosage-related adverse effects include double 
or blurred vision, dizziness, sedation, ataxia, vertigo, gastrointes-
tinal disturbances, cognitive impairment, hematological effects, 
and Stevens-Johnson syndrome including its related dermato-
logic effects (Tohen et al., 1991, 1995; Blackburn et al., 1998).
The most significant drawback of lamotrigine treatment is the 
need to initiate it at 25 mg/d for 2 weeks, then 50 mg/d for another 
2 weeks and then by increments of 25 to 50 mg/d thereafter to 
avoid a moderately high incidence of rash (Seo et al., 2010).
Carbamazepine decreases lamotrigine concentrations by 
approximately 50%, and in combination therapy, lamotrig-
ine can be started with higher dosages and faster titration. 
Vice versa, when combined with valproate a slower titration 
scheme is needed for lamotrigine, carbamazepine induces the 
metabolism of other agents as well, for example, risperidone 
(Ono et al., 2002).
It is also important to note the adverse effects of topiramate 
because although it is not used in the treatment of BD per se, 
it is often administered in BD patients in order to lose weight 
or to treat a comorbid substance abuse disorder. It is reported 
that topiramate impairs attention, verbal memory, psychomotor 
speed, and word-finding even at very low dosages (25–50 mg/d). 
This impairment is reversible after discontinuation of the drug 
(Salinsky et al., 2005; Goldberg, 2008).
An important recent development was the safety warning by 
the FDA after a meta analysis that suggested that antiepilep-
tics might double the suicidal risk (FDA, 2008). The field remains 
uncertain, with some reports and authors supporting the FDA 
warning (Nilsson et  al., 2002; Mula and Sander, 2007; Gibbons 
et  al., 2009; Andersohn et  al., 2010; Arana et  al., 2010; Olesen 
et al., 2010; Patorno et al., 2010; VanCott et al., 2010; Ziemba et al., 
2010; Wen et al., 2011; Fountoulakis et al., 2012c; Pugh et al., 2012; 
Siamouli et al., 2014). It is important to note that suicidality data 
came from the registration of adverse events rather than from 
systematically collected data (Hesdorffer and Kanner, 2009). 
However, it seems clear that topiramate, lamotrigine, and lev-
etiracetam are related to increased suicidality in nonpsychiatric 
patients and this should be the focus of further research.
Antipsychotics
The adverse effects of FGAs include EPS, tardive dyskinesia, and 
hyperprolactinaemia and the life-threatening but rather rare 
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Table 9. Grading of Treatment Options According to Safety Issues (According to the System Shown in Table 1)
Agent/modality
(alphabetical order) Grade Comments
Agomelatine 2 Liver enzymes induction
Allopurinol 2 Swelling of mouth and lips, severe skin rashes, infections, eye irritation, hepatitis, appetite and weight 
loss, and painful or bloody urination
Aripiprazole 1
Armodafinil/modafinil 2 Stimulant, risk for abuse
Asenapine 1
Bupropion 1
Carbamazepine 2 Hepatic enzymes induction, many adverse effects
Cariprazine 1
Celecoxib 1
Chlorpromazine 1
Clozapine 3 Potentially lethal agranulocytosis, metabolic syndrome
Donepezil 1
ECT 2 Not preferred by patients, mild cognitive problems
Escitalopram 1
Eslicarbazepine 1
Fluoxetine 1
FEWP 1
Gabapentin 1
Haloperidol 2 EPS, Tardive dyskinesia, neuroleptic malignant syndrome, switch risk
Imipramine 2 Cardiac side effects, many adverse effects, switch risk
Ketamine 3 Stimulant
L-sulpiride 1
Lamotrigine 2 Good overall tolerability but potentially lethal skin reaction that can be avoided by slow titration
Levetiracetam 3 Induction of suicidality
levothyroxine (L-T4) 2 Mild cardiovascular, skin and bone adverse effects
Licarbazepine 1
Lisdexamfetamine 3 High risk for abuse and dependence
Lithium 2 Many adverse effects, weight gain, toxicity
Loxapine inhalant 1
Lurasidone 1
N-acetyl cysteine 1
Memantine 1
Medroxyprogesterone 1
Modafinil 2 Stimulant, risk for abuse
Olanzapine 2 Metabolic syndrome
Oxcarbazepine 1
Paliperidone 1
Paroxetine 1
Perphenazine 2 Switch risk, EPS, tardive dyskinesia, neuroleptic malignant syndrome
Phenytoin 2 Many adverse effects
Phenelzin 2 Many adverse effects
Pimozide 2 EPS, tardive dyskinesia, neuroleptic malignant syndrome
Pioglitazone 2 Not recommended in patients with diabetes mellitus type I and in liver disease. Absolute 
contraindication in heart failure patients
Pramipexole 2 Adverse effects include the induction of problematic behaviours and psychotic symptoms
Pregnenolone 2 Not well studied
Quetiapine 1
Risperidone 1
RLAI 1
Sertraline 1
Tamoxifen 3 Deep vein thrombosis, cognitive disorder
TMS 1
Topiramate 3 Induction of depression and suicidality
Tranylcypromine 2 Many adverse effects
Valproate 1 Cautious use in women of childbearing age
Venlafaxine 2 Switch risk
Verapamil 1
Ziprasidone 2 QTc prolongation, patients should undergo cardiologic examination before receiving ziprasidone
Abbreviations: ECT, electroconvulsive therapy; EPS, extrapyramidal signs; FEWP, Free and Easy Wanderer Plus; RLAI, risperidone long-acting injectable; TMS, transcra-
nial magnetic stimulation.
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neuroleptic malignant syndrome, while the most frequent side 
effects of chlorpromazine are EPS, tardive dyskinesia, postural 
hypotension, and hepatotoxicity.
On the other hand, the most significant problem with some 
of the SGAs is weight gain, hyperlipidaemia, and diabetes mel-
litus. The treatment of these somatic conditions is difficult and 
the methods proposed have produced rather unsatisfactory 
results so far. Hyperprolactinaemia and EPS are the most fre-
quent adverse effects with amisulpride. Akathisia and EPS are 
the adverse effects most often reported with aripiprazole.
Concerning olanzapine, the most frequent adverse effects 
include dry mouth, weight gain, increased appetite, diabetes 
mellitus and metabolic syndrome, and somnolence. The main 
adverse effects of quetiapine are persistent sedation and weight 
gain, however, to a lower extent than olanzapine. Maybe the XR 
formulation of quetiapine induces less sedation in comparison 
with the IR formulation (Riesenberg et al., 2012). The main side 
effects of risperidone are dose-related EPS, weight gain, sedation, 
and hyperprolactinemia. Somnolence, akathisia, and EPS as well 
as a significant QTc prolongation are the main adverse effects 
of ziprasidone treatment; however, ziprasidone is not associated 
with the metabolic syndrome (Kemp et al., 2012a).
Reports on antipsychotics concerning adverse effects on neu-
rocognition are rare and conflicting (Holmes et al., 2008; Goldberg 
and Chengappa, 2009; Pan et al., 2011). There are data suggest-
ing that an executive function deficit is correlated with years of 
exposure to antipsychotic drugs (Zubieta et al., 2001). This latter 
finding could reflect either the toxic effect of chronic psychosis, 
the toxic effect of long-term medication, or both. Current antip-
sychotic treatment in BD patients is reported to relate to worse 
performance in sustained attention and visuomotor speed, 
across all executive function tests as well as in semantic fluency, 
verbal learning, and recognition memory, even when studies 
were controlled for differences in clinical features (King, 1994; 
Altshuler et al., 2004; Frangou et al., 2005; Jamrozinski et al., 2009).
Antidepressants
There is a number of different adverse effects caused by anti-
depressants. Most of them are not severe and may cause sig-
nificant burden to the patients but usually improve with time 
(NHS, 2014).
The adverse effects of SSRIs and serotonin and norepinephrine 
re-uptake inhibitors include agitation, shakiness, anxiety or feeling 
of being sick, indigestion, stomach aches, diarrhoea or constipa-
tion, loss of appetite, dizziness, insomnia and other sleep disor-
ders, or, on the contrary, hypersomnia and sedation, headache, loss 
of libido, weight gain, excessive sweating, hyponatriaemia (espe-
cially in the elderly), and sexual dysfunction. The adverse effects 
of tricyclic antidepressants include: dry mouth, blurred vision, 
constipation, dysuria, drowsiness, dizziness, weight gain, exces-
sive sweating, and heart rhythm problems. A rare but potentially 
life-threatening adverse event is the serotonin syndrome whose 
symptoms include confusion, agitation, muscle twitching, sweat-
ing, shivering, and diarrhea. Rare but serious cases may mani-
fest with very high fever, epileptic fits, arrhythmia, and coma. All 
classes of antidepressants have been linked to an increased risk of 
developing type 2 diabetes, but the causality is uncertain.
There is a warning issued by the FDA (black box warning) con-
cerning the risk of suicidality in pediatric patients taking SSRIs 
for depression (Libby et al., 2007), and a number of papers sug-
gest that antidepressants are related to an increased risk for sui-
cidal behavior (Rouillon et al., 1991; Khan et al., 2000, 2001, 2003; 
Luoma et  al., 2002; Baldessarini et  al., 2003a; Healy, 2003) but 
not for completed suicide (Whittington et al., 2004). This might 
constitute one of the most interesting paradoxes of our contem-
porary psychiatry, since antidepressants prevent suicidal behav-
ior among severely ill, frequently suicidal “real life” unipolar 
depressives but may provoke such behavior sometimes in less 
severe, actually nonsuicidal unipolar depressives (Leon et  al., 
1999; Angst et al., 2002; Yerevanian et al., 2004; Simon et al., 2006; 
Gibbons et al., 2007). It has been suggested that antidepressants 
induce suicidality essentially only in pseudo-unipolar patients 
(Akiskal and Benazzi, 2005; Rihmer and Akiskal, 2006; Perlis et al., 
2007b), while the data from the STAR*D trial suggest the presence 
of a genetic vulnerability predisposing to the manifestation of 
new suicidal ideation after antidepressant treatment (Laje et al., 
2007; Perlis et al., 2007a, 2007b).
Switching to the Opposite Pole
It is widely accepted among psychiatrists that both antidepres-
sants and FGAs can induce a mood switch to the opposite pole, 
or a chronic, dysphoric, mixed, or irritable state in BD patients 
and may accelerate episode frequency and/or may cause other 
forms of course destabilization in patients with BD. However, 
hard evidence is limited and the bulk of evidence comes from 
chart reviews and retrospective and open studies. A comprehen-
sive summary of the risk to induce switching for all agents dur-
ing the 3 phases of treatment is shown in Table 10.
The literature suggests that without the concomitant use 
of an antimanic agent the switch rate to mania or hypomania 
is around 20 to 40% (Bottlender et al., 2001, 2004; Goldberg and 
Truman, 2003), while with the concomintant use of an antimanic 
Table 10. Risk of Various Agents to Induce the Opposite Mood Pole 
(Switch Risk)
Treatment phase
Agent/modality  
(alphabetical order)
Acute  
mania Depression Maintenance
Aripiprazole 5 5 5
Asenapine 5 - 5
Bupropion - 5 -
Carbamazepine 5 - 5
ECT - 4 -
Escitalopram - 5 -
Fluoxetine - - 5
Haloperidol 4 - 4
Imipramine - 3 2
Lamotrigine 5 - 5
Lithium 5 - 5
OFC - 5 5
Olanzapine 5 5 5
Paliperidone 5 - 5
Paroxetine - 5 5
Perphenazine 4 - 2
Quetiapine 5 5 5
RLAI 5 - 5
Sertraline - - 5
Valproate 5 - 5
Venlafaxine - 3 -
Ziprasidone 5 - 5
Abbreviations: -, no data; ECT, electroconvulsive therapy; OFC, olanzapine-
fluoxetine combination; RLAI, risperidone long-acting injectable.
The treatment options are rated in an analogous way to the rating system 
shown in Table 1 as “efficacy to induce the opposite pole.”
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agent the rate is reduced to 14% or below (Nemeroff et al., 2001; 
Post et al., 2001, 2006; Harel and Levkovitz, 2008; Licht et al., 2008; 
Tondo et al., 2010). More recent reports suggest that switching 
is exclusively related to antidepressant monotherapy, while the 
concomitant use of an antimanic agent has a robust protective 
effect (Viktorin et al., 2014). The results of the STEP-BD support 
the potentially harmful role of antidepressants in the long-term 
course of BD (Truman et al., 2007; El-Mallakh et al., 2008, 2015). 
According to that study switching to the opposite pole was 
not dose dependent (Tada et  al., 2015). However, a number of 
larger RCTs reported negative data concerning switching with 
paroxetine and bupropion (Sachs et al., 2007), fluoxetine, even 
as monotherapy in BD-II patients (Amsterdam et al., 2004), and 
citalopram (Schaffer et al., 2006). There are some data suggest-
ing a higher risk of switching while on treatment with venla-
faxine (Amsterdam and Garcia-Espana, 2000; Vieta et al., 2002; 
Altshuler et al., 2006, 2009; Leverich et al., 2006; Post et al., 2006) 
and imipramine (Himmelhoch et al., 1991; Nemeroff et al., 2001; 
Silverstone, 2001), but a more recent study reported that ven-
lafaxine was equal to lithium and without any increase in the 
switch rate (Lorenzo-Luaces et al., 2016).
It is important to mention that switching to mania or hypo-
mania during treatment of comorbid OCD (White et  al., 1986; 
Steiner, 1991; Vieta and Bernardo, 1992; Rihmer et al., 1996; Perugi 
et  al., 2002) or panic disorder with antidepressants have been 
reported (Pecknold and Fleury, 1986; Sholomskas, 1990).
The switch risk is probably as high as 18.2% in the short term 
and 35.6% during the continuation phase (Post et al., 2003) and is 
higher in BD-I patients in comparison with BD-II (14.2% vs 7.1% 
in acute trials and 23.4% vs 13.9% in maintenance studies). The 
rates of switching in unipolar patients are lower than those of 
bipolar (1.5% in acute trials and 6.0% in maintenance studies) 
(Bond et al., 2008; Tondo et al., 2010).
Table  11. Levels of Recommendation Concerning Monotherapy in 
Acute Mania and Recommended Dosages for Medication Options
Agent/modality
Recommendation
level
Recommended  
dosage (mg/d)
Aripiprazole 1 15–30 mg/d
Asenapine 1 10–20 mg/d
Cariprazine 1  3–12 mg/d
Paliperidone 1  3–12 mg/d
Quetiapine 1 400–800 mg/d
Risperidone 1 2–6 mg/d
Valproate 1 1200–3000 mg/d (loading 
dose 20–30 mg/kg body 
weight; serum level 
75–150 mg)
Carbamazepine 2 600–1200 mg/d (serum level 
4–15 mg/L)
Haloperidol 2 5–20 mg/d
Lithium 2 600–1200 mg/d (serum level 
0.8–1.3 mmol)
Olanzapine 2 10–20 mg/d
ECT 3
Oxcarbazepine 4 900–1800 mg/d
Chlorpromazine 4 300–1000 mg/d
Pimozide 4 2–16 mg/d
Tamoxifen 4 40–80 mg/d
Ziprasidone 4 80–160 mg/d`
Eslicarbazepine 5
Gabapentin 5
Lamotrigine 5
Licarbazepine 5
TMS 5
Topiramate 5
Verapamil 5
Abbreviations: ECT, electroconvulsive therapy; NR: not recommended; TMS, 
transcranial magnetic stimulation.
Table  12. Recommendation levels for combination treatment for 
acute mania
Agent/modality MS Li Val Cbz FGAs
Asenapine 1 - - - -
Haloperidol 2 2 2 2 -
Olanzapine 2 - 2 5 -
Aripiprazole 2 - - - -
Medroxyprogesterone 5 - - - -
Celecoxib - - 2 - -
Quetiapine 3 3 - - -
Risperidone 3 - 5 - -
Tamoxifen 4 4 - - -
Allopurinol 5 2 - - 5
Paliperidone 5 - - - -
Ziprasidone 5 - - - -
Gabapentin 5 - - - -
Topiramate 5 - - - -
Lamotrigine - - - - -
Lithium - - - 2 -
Oxcarbazepine - 4 - - -
Valproate - - - - 2
Abbreviaitons: Cbz, carbamazepine; FGA, first generation antipsychotic; Li, 
lithium; MS, mood stabilizer; Val, valproate.
Table 13. Recommendation Levels for Monotherapy in Rapid Cycling 
Patients in an Acute Manic Episode
Agent/modality
Recommendation
level
Quetiapine 3
Aripiprazole 3
Olanzapine 3
Valproate 4
Lithium 4
Table 14. Recommendation Levels for Monotherapy in Patients in an 
Acute Manic Episode and the Specific Effect on Concomitant Depres-
sive Symptoms (Mixed Features) and Psychotic Features
Agent/modality
Therapeutic effect on
Overall on
manic episode
Concomitant  
Depressive
symptoms
Psychotic
symptoms
Quetiapine 1 3 3
Risperidone 1 3 3
Aripiprazole 1 5 3
Asenapine 1 5 -
Olanzapine 2 3 3
Carbamazepine 2 5 -
Cariprazine 1 5 -
Haloperidol 2 5 3
Lithium 2 5 3
Tamoxifen 4 5 4
Valproate 1 5 -
Ziprasidone 2 5 3
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Haloperidol and perphenazine treatment have been asso-
ciated with the development of dysphoria and depression, 
although the data are inconclusive for haloperidol (Tohen et al., 
2003b; Zarate and Tohen, 2004). On the contrary, SGAs do not 
appear to induce depression, while some authors suggest they 
possess a mild protective property against switching (Tohen 
et  al., 2003c; Amsterdam and Shults, 2005a; Calabrese et  al., 
2005b; Keck et al., 2005; Thase et al., 2006; Benazzi et al., 2009). 
A recent meta-analysis reported that treating acute mania with 
SGAs is associated with a 42% lower risk of switch to depression 
than with haloperidol. Nevertheless, caution should be taken 
when considering this to be a class effect, as only olanzap-
ine, quetiapine, and ziprasidone may show these advantages 
(Goikolea et al., 2013b).
Overall there are no data to suggest a generalized and class 
effect for antidepressants or FGAs concerning the induction of 
an affective switch. There are negative data concerning all SSRIs 
and SGAs studied and positive data only concerning venlafax-
ine, imipramine, and perphenazine. Some authors believe that at 
least the switch risk and perhaps also the risk for rapid cycling 
and new-onset suicidality have been overinterpreted (Grunze, 
2008), and thus the issue of switching is still open and further 
research is needed. Also negative for the presence of a treat-
ment-induced switch are the longitudinal data of Jules Angst 
(Angst, 1985). For a safe use of antidepressants in BD, clinicians 
may follow the recommendations of the International Society for 
Bipolar Disorders Task Force (Pacchiarotti et al., 2013).
Review of Existing Guidelines for BD
A number of treatment guidelines were identified and their refer-
ence lists were utilized (APA, 1994, 1995, 2002; Suppes et al., 1995, 
2001, 2002, 2003; Frances et al., 1996; 1997; AACAP, 1997; Goodwin 
et al., 1997, 2003, 2009, 2016; Jobson, 1997; Kusumakar et al., 1997; 
McClellan and Werry, 1997; Gilbert et  al., 1998; Barreira et  al., 
1999; Bauer et al., 1999b; Rush et al., 1999, 2003; Dennehy, 2000; 
Goldberg, 2000; Sachs et al., 2000; Allen et al., 2001; Montgomery, 
2001; Grunze et al., 2002, 2003, 2004, 2009, 2010, 2011, 2013; Licht 
et al., 2003; Hirschfeld, 2005; Yatham et al., 2005, 2006, 2008, 2009, 
2013b, 2013c; National Collaborating Centre for Mental Health, 
2006; O’Dowd, 2006; Nolen et al., 2008; Jon et al., 2009; Ng et al., 
2009; Beaulieu et al., 2012; Bond et al., 2012; McIntyre et al., 2012b; 
Rosenbluth et  al., 2012; Schaffer et  al., 2012; Mohammad and 
Osser, 2014; Malhi et al., 2015; Ostacher et al., 2015a; Woo et al., 
2015). An additional source was the National Institute of Clinical 
Excellence (NICE) guideline concerning BD (NICE, 2014), while 
the latest version of the guidelines of the British Association 
of Psychopharmacology (Goodwin et  al., 2016) were included, 
although they were published after the date of last literature 
search.
A description of the most important and most recent guide-
lines (after 2005)  will be included in the text that follows. In 
Tables 17, 21, and 25 there is a detailed description of difference 
between the current CINP guidelines and previously developed 
guidelines by other bodies.
American Psychiatric Association Treatment 
Guidelines for BD
In 2008 the APA developed a draft of new guidelines after a thor-
ough review of the literature. However, they were never pub-
lished because of unresolved issues pertaining to the conflict of 
interest.
The Canadian Network for Mood and Anxiety 
Treatments and International Society on Bipolar 
Disorder Guidelines
The most recent 2013 version of the Canadian Network for Mood 
and Anxiety Treatments and International Society on Bipolar 
Disorder guidelines (Yatham et al., 2013c) suggests that for the 
treatment of acute manic episodes the first line recommendation 
is monotherapy with lithium, divalproex, divalproex ER, olanzap-
ine, risperidone, quetiapine, quetiapine XR, aripiprazole, ziprasi-
done, asenapine, or paliperidone ER, and adjunctive therapy with 
risperidone, quetiapine, olanzapine, aripiprazole, asenapine on 
lithium, or divalproex. The second line includes monotherapy 
with carbamazepine, carbamazepine ER, ECT, or haloperidol and 
combination therapy with lithium plus divalproex. The third line 
of treatment includes monotherapy with chlorpromazine, clo-
zapine, oxcarbazepine, tamoxifen, or cariprazine and combina-
tion therapy with lithium or divalproex plus haloperidol, lithium 
plus carbamazepine, or adjunctive tamoxifen. They do not rec-
ommend monotherapy with gabapentin, topiramate, lamotrigine, 
verapamil, or tiagabine and combination therapy with risperi-
done or olanzapine plus carbamazepine.
Table 15. Recommendation Levels for Monotherapy and Combination Treatment in Patients in a DSM-IV-TR Mixed Episode and the Specific 
Effect on the Manic and the Depressive Component
Monotherapy Combination with MS
Agent/modality Manic component Depressive component Manic component Depressive component
Olanzapine 3 3 2 2
Asenapine 3 3 - -
Aripiprazole 3 3 - -
Carbamazepine 3 3 - -
Valproate 3 4 - -
Paliperidone 3 5 - -
Risperidone 3 - 5 5
OFC 4 4 - -
Ziprasidone 4 4 - -
Lithium 5 - - -
Quetiapine 5 - - -
Celecoxib - - 5 5
Haloperidol - - 5 5
Abbreviations: MS, mood stabilizer; OFC, olanzapine-fluoxetine combination.
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Table 16. Precise Evidence-Based Alrogithm to Treat Acute Manic Episodes on the Basis of Specific Clinical Characteristics
Step First Second Third Fourth Fifth
All cases Discontinue treatment 
with antidepressants
Rapid cycling Start with aripiprazole 
or quetiapine 
monotherapy. In 
nonpsychotic cases 
valproate is also 
an option Take into 
consideration the 
previous history of 
psychotic features.
Olanzapine or lithium 
monotherapy
Combination 
treatment of 
lithium or 
valproate with 
quetiapine, or 
risperidone.
Apply ECT on top of 
pharmacological 
treatment. 
Monotherapy with 
chlorpromazine, 
pimozide, or 
tamoxifen. Options 
are also combination 
treatments of 
lithium or valproate 
plus tamoxifen or 
the combination 
of risperidone or 
oxcarbazepine plus 
lithium
Various combinations of 
medication according to 
anecdotal knowledge or the 
personal experience of the 
therapist, ECT if not applied 
earlier
Nonrapid cycling 
with psychotic 
features
Start with aripiprazole, 
cariprazine, 
paliperidone, 
quetiapine, or 
risperidone 
monotherapy.
Monotherapy with 
haloperidol, 
lithium, olanzapine 
or ziprasidone 
or combination 
treatment of 
lithium or valproate 
with aripiprazole, 
haloperidol or 
olanzapine. Lithium 
combinations with 
allopurinol* is also 
an option. Another 
combination is 
valproate plus an 
FGA.
Nonrapid cycling 
without 
psychotic 
features
All options that 
are suitable in 
the presence of 
psychotic features 
and also valproate 
and asenapine 
monotherapy are 
a choice. Take into 
consideration the 
previous history of 
psychotic features.
All options that are 
suiTable in the 
presence of psychotic 
features and also 
monotherapy with 
carbamazepine 
or valproate plus 
celecoxib* are an 
option Take into 
consideration the 
previous history of 
psychotic features.
Mixed Features Start with quetiapine 
or risperidone 
monotherapy.
Olanzapine 
monotherapy
All other cases If the patient is already 
under one of the 
above ‘first step’ 
monotherapy or 
under combination 
therapy of any 
kind and response 
is unsatisfactory, 
switch into 
another ‘first step’ 
monotherapy.
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Step First Second Third Fourth Fifth
In case the 
personal 
history of 
the patient 
suggests this is 
not an option, 
proceed to 
next step and 
switch to the 
closest second 
step treatment 
option.
Proceed to next step
Mixed episode Start with combination 
of olanzapine plus 
valproate or maybe 
lithium
Monotherapy with 
olanzapine, 
aripiprazole, or 
carbamazepine.
Valproate 
monotherapy
OFC or ziprasidone 
monotherapy.
Abbreviations: CBT, cognitive behavioral treatment; Cbz, carbamazepine; ECT, electroconvulsive therapy; IPSRT, InterPersonal and Social Rhythms Therapy; Lam, 
lamotrigine; Li, lithium; MS, mood stabilizer; OFC, olanzapine fluoxetine combination; rTMS, repetitive Transcranial Magnetic Stimulation; Val, valproate.
* No wide clinical experience.
Table 16. Continued
Table 17. Comparison of the Detailed Algorithm to Previously Developed Guidelines for Acute Mania
CINP
2016
WFSBP
2013a
CANMAT and
ISBD 2013 NICE 2014b
BAP
2016b
Aripiprazole 1 1 1 - 3
Asenapine 1 3 1 - 3
Cariprazine 1 - 3 - 3
Paliperidone 1 3 1 - 3
Quetiapine 1 3 1 1 1
Risperidone 1 1 1 1 1
Valproate 1 1 1 1 2
Carbamazepine 2 3 2 - 3
Haloperidol 2 3 2 1 1
Lithium 2 3 1 1 3
Olanzapine 2 3 1 1 1
Ziprasidone 2 1 1 - 3
ECT 3 4 2 - 3
Oxcarbazepine 4 4 3 - -
Chlorpromazine 4 3 3 - 3
Pimozide 4 3 - - 3
Tamoxifen 4 3 3 - -
Eslicarbazepine NR  - - - -
Gabapentin NR NR NR NR -
Lamotrigine NR NR NR NR -
Licarbazepine NR - - - -
rTMS NR - - - -
Topiramate NR NR NR NR -
Verapamil NR  - - - -
Phenytoin - 3 - - -
Clozapine  - 4 3 - 3
Amisulpride  - 4 - - 3
Clonazepam  - 4 - - -
Leviracetam  - 4 - - -
Lorazepam  - 4 - - -
Abbreviations: ECT, electroconvulsive treatment; NR, not recommended;
rTMS, repetitive Transcranial Magnetic Stimulation.
The grading is not uniform; instead it reflects the grading utilized by individual guidelines and the table aims only to give an image of how different guidelines prior-
itize treatment options.
Numbers correspond to steps not to efficacy ranking.
a NICE and BAP ordering is on the basis of line of treatment.
b Step 2 in the WFSBP guideline would be a combination of 2 grade “1” recommended medication, or switch from one grade “1” medication to another.
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For the treatment of acute BD-I depression as first line option 
they recommend monotherapy with lithium, lamotrigine, que-
tiapine, or quetiapine XR and combination therapy with lithium 
or divalproex or olanzapine plus an SSRI, lithium plus dival-
proex and lithium, or divalproex plus bupropion. The second 
line includes monotherapy with divalproex or lurasidone and 
combination therapy with quetiapine plus an SSRI, adjunctive 
modafinil, and lithium or divalproex plus lamotrigine or lurasi-
done. The third line includes monotherapy with carbamazepine, 
olanzapine, or ECT or combination therapy with lithium plus 
carbamazepine or pramipexole, lithium or divalproex plus venla-
faxine, lithium plus MAOI, lithium or divalproex or atypical antip-
sychotic plus a TCA, lithium or divalproex or carbamazepine plus 
an SSRI plus lamotrigine, and quetiapine plus lamotrigine. They 
do not recommend monotherapy with gabapentin, aripiprazole, 
or ziprasidone and combination therapy with adjunctive ziprasi-
done or levetiracetam.
For the maintenance treatment, the first line recom-
mendation includes monotherapy with lithium, lamotrigine, 
divalproex, olanzapine, quetiapine, risperidone LAI, and ari-
piprazole and adjunctive therapy with quetiapine, risperidone 
LAI, aripiprazole,e or ziprasidone on lithium or divalproex. The 
second line monotherapy includes carbamazepine and pali-
peridone ER and combination therapy with lithium plus dival-
proex or carbamazepine, lithium or divalproex plus olanzapine, 
risperidone or lamotrigine, and olanzapine plus fluoxetine. The 
third line monotherapy includes asenapine and the adjunc-
tive therapy includes phenytoin, clozapine, ECT, topiramate, 
omega-3-fatty acids, oxcarbazepine, gabapentin, and asenapine. 
They do not recommend monotherapy with gabapentin, 
topiramate, or antidepressants and adjunctive therapy with 
flupenthixol.
The World Federation of Societies of Biological 
Psychiatry (WFSBP) Guidelines for the Biological 
Treatment of BD
The latest WFSBP guidelines utilized a modified version of the 
PORT method to grade the data concerning efficacy (Grunze 
et al., 2009, 2010, 2013) and afterwards utilized a secondary clas-
sification to include also safety and tolerability.
For the treatment of acute mania, as first choice agents 
are ranked aripiprazole, valproate, risperidone, and ziprasi-
done. As second choice, olanzapine, quetiapine, asenapine, 
Table 18. Level of Recommendation Concerning Monotherapy in Acute Bipolar Depression, in Comorbid Conditions and Rapid Cycling Patients, 
and Recommended Dosages for Medication Options
Agent/modality Overall BD-I BD-II
Depressive
core
Comorbid
anxiety
Rapid
cycling
Recommended
dosage (mg/d)
Quetiapine 1 3 3 3 3 2 300–600 mg/d
Lurasidone 1 - - 3 3 - 20–120 mg/d
OFC 2 2 - 3 - - 6 + 25; 6 + 50; 12 + 50 mg/d
Escitalopram - - 1 - - - 10 mg/d
Fluoxetine 2 - 3 - - - 20–80 mg/d
Olanzapine 2 4 - 3 - - 5–20 mg/d
Carbamazepine 3 - - - - - 300–800 mg/d
Valproate 3 3 5 3 3 4 500–2500 mg/d (50–100 mcg/mL)
Aripiprazole 3 3 - - - - 5–30 mg/d
Imipramine 3 - - - - - 75–300 mg/d
Lamotrigine 3 3 3 3 - - 50–200 mg/d
Phenelzine 3 - - - - - 15–90 mg/d
Lithium 4 - 4 - 5 3 600–1800 mg/d
Tranylcypromine 4 4 4 - - - 20–30 mg/d
Venlafaxine 4 4 4 - - - 75–225 mg/d
Paroxetine 5 5 5 - 3 5 20 mg/d
Ziprasidone 5 5 - - 5 -
Gabapentin 5 - - - - -
rTMS 5 - - - - -
Risperidone - - - - 5 -
Abbreviations: NR, not recommended; OFC, olanzapine-fluoxetine combination; rTMS, repetitive Transcranial Magnetic Stimulation.
Table  19. Level of Recommendation Concerning Combination 
Treatment in Acute Bipolar Depression
Agent/modality MS Cbz Lam Li Val
Lurasidone 2 - - - -
Modafinil 2 - - - -
Pramipexole 2 - - - -
Pioglitazone - - - 2 -
Armodafinil 4 - - - -
Ketamine 4 - - - -
Paroxetine 5 5 - 5 5
Ziprasidone 5 - 5 5 5
Bupropion 5 - - - -
Celecoxib 5 - - - -
Levetiracetam 5 - - - -
Levothyroxine (L-T4) 4 - - - -
Risperidone 5 - - - -
Lithium - - 2 - -
Memantine - - 5 - -
FEWP - 4 - - -
Oxcarbazepine - - - 4 -
Lamotrigine - - - 2 -
L-sulpiride - - - 3 -
Fluoxetine - - - 4 -
Agomelatine 5 - - 5 5
Aripiprazole - - - 5 -
Imipramine - - - 5 -
Abbreviations: Cbz, carbamazepine; FEWP, Free and Easy Wanderer Plus (herbal 
agent); Lam, lamotrigine; MS, mood stabilizer; Val, valproate.
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carbamazepine, haloperidol, and lithium were recommended. 
The third choice includes chlorpromazine, paliperidone, phe-
nytoin, pimozide, and tamoxifen. The fourth includes ami-
sulpride, clonazepam, clozapine, levetiracetam, lorazepam, 
nimodipine, oxcarbazepine, retigabine, zonisamide, zotepine, 
and ECT. The fifth and final choice includes verapamil. With 
the utilization of this classification, the WFSBP suggests that 
concerning the treatment of acute mania the first step includes 
Table 20. Precise Algorithm to Treat Acute Bipolar Depressive Episodes on the Basis of Specific Clinical Characteristics
Steps First Second Third Fourth Fifth
Overall Start with quetiapine or 
lurasidone
Consider CBT as add-on 
to medication and 
according to the 
patient preference 
and to availability. 
Never consider CBT as 
monotherapy
Add a mood stabilizer on 
lurasidone, modafinil or 
pramipexole
Lithium plus lamotrigine, 
or pioglitazone*
Olanzapine monotherapy 
or OFC
Valproate, aripiprazole, 
imipramine, phenelzin, 
carbamazepine 
or lamotrigine 
monotherapy
Lithium plus L-sulpiride
Tranylcypromine or lithium 
monotherapy
Venlafaxine preferably in 
combination with an 
antimanic agent
Armodafinil or ketamine on 
a mood stabilizer
Lithium plus fluoxetine
Carbamazepine plus FEWP
Mood stabilizer plus 
levothyroxine (L-T4)
Lithium plus oxcarbazepine
ECT or various 
combinations 
of medication 
according to 
anecdotal 
knowledge or 
the personal 
experience of the 
therapist
Rapid cycling If BD-I start with 
valproate, in BD-II with 
lithium
No rapid 
cycling
If BD-II start with 
escitalopram or 
fluoxetine monotherapy
Comorbid
anxiety
Add paroxetine, 
quetiapine, valproate or 
lurasidone and consider 
Mindfulness based 
interventions as add-on 
to these agents
Abbreviations: CBT, cognitive behavioral treatment; Cbz, carbamazepine; ECT, electroconvulsive therapy; FEWP, Free and Easy Wanderer Plus (herbal agent); IPSRT, 
InterPersonal and Social Rhythms Therapy; Lam, lamotrigine; Li, lithium; MS, mood stabilizer
OFC, olanzapine fluoxetine combination; rTMS, repetitive Transcranial Magnetic Stimulation; Val, valproate.
* No wide clinical experience.
Table 21. Comparison of the Presise Algorithm to Previously Developed Guidelines for Acute Bipolar Depression Concerning Monotherapy
CINP
2016
WFSBP
2013a
CANMAT and
ISBD 2013 NICE 2014b
BAP
2016b
Lurasidone 1 - 2 - 1
Quetiapine 1 1 1 1 1
Escitalopram 2c - - - 3
Fluoxetine 2c 1 - - 3
Olanzapine 2 1 3 1 1
OFC 2 1 1 1 1
Aripiprazole 3 NR NR - -
Imipramine 3 4
Lamotrigine 3 1 1 1 2
Phenelzin 3 -
Valproate 3 1 2 1 -
Carbamazepine 3 1 3 - -
Lithium 4 1 1 1 3
Tranylcypromine 4 - - - 4
ECT 5 - 3 - 5
Gabapentin NR - NR - -
Leviracetam - - NR - -
L-thyroxine - - - - -
Paroxetine NR NR - - 3
Risperidone - - NR - -
rTMS NR - - - -
Ziprasidone NR NR NR - -
Abbreviations: ECT, electroconvulsive treatment; NR, not recommended;
OFC, olanzapine-fluoxetine combination; rTMS, repetitive Transcranial Magnetic Stimulation.
The grading is not uniform; instead it reflects the grading utilized by individual guidelines and the table aims only to give an image of how different guidelines prior-
itize treatment options. Numbers correspond to steps not to efficacy ranking.
a WFSBP: Recommendation only reflects monotherapy not considering evidence derived from combination treatment (except OFC).
b NICE and BAP ordering is on the basis of line of treatment.
c Against BD-II depression.
NICE ordering is on the basis of line of treatment.
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monotherapy with first choice agents. The second step would 
be switching to another first-choice agent or combine 2 first 
choice agents. Similarly the third step includes combination of 
2 first-choice agents. The fourth and fifth steps include com-
binations of agents essentially according to the judgement of 
the therapist.
For the treatment of acute bipolar depression, the WFSBP 
guidelines suggest that first choice agent is only quetiapine, 
while the next-best option includes olanzapine, fluoxetine, 
lamotrigine, valproate, OFC, lithium plus lamotrigine, adjunc-
tive modafinil, NAC on lithium or valproate, and FEWP plus 
carbamazepine. A  variety of combinations are proposed as 
next steps.
For the treatment during the maintenance phase the 
guidance is more complex and on the basis of the available 
data the WFSBP guidelines suggest the use of aripiprazole, 
lamotrigine, lithium, quetiapine, olanzapine, and risperidone, 
but they note that not all of them prevent both mania and 
depression. They also note the problems because of the meta-
bolic syndrome induced by some of these agents when used 
for prolonged periods of time. They also suggest the avoidance 
of typical antipsychotics because of the risk to induce tardive 
dyskinesia.
British Association for Psychopharmacology
The 2016 British Association for Psychopharmacology guidelines 
for the treatment of BD (Goodwin et  al., 2016) recommend for 
acute mania antidopaminergic agents, lithium, or valproate. For 
acute bipolar depression they recommend quetiapine, olanzap-
ine, olanzapine plus fluoxetine, antidepressants, lurasidone, and 
lamotrigine as combination. It also recommends family focused 
therapy, IPSRT, and CBT as add-on to medication but also CBT as 
monotherapy as an extrapolation of unipolar depression studies. 
For the maintenance phase they recommend lithium (for mania, 
depression, and suicide), dopamine antagonists, and partial ago-
nists as well as valproate (mainly for mania), lamotrigine (for 
depression), and family focused therapy, CBT, and IPSRT as add-
on to medication.
The UK NICE Treatment Guidelines for BD
Concerning acute mania, the 2014 NICE (NICE, 2014) guidelines 
recommend the use of olanzapine, risperidone, quetiapine, or 
haloperidol. If the patient does not respond it is recommended to 
change to another antipsychotic, and the choice should be made 
also on the basis of previous response if it exists. If the patient 
is already under treatment with lithium or valproate then the 
recommendation is to increase dosage to the highest permitted, 
and reassessment should follow before the changing of medica-
tion. If an antidepressant is in place, it should be discontinued. 
The second step includes combination of lithium or valproate 
plus an antipsychotic and the third step demands hospitaliza-
tion. The NICE warns against the use of gabapentin, lamotrigine, 
and topiramate in acute mania.
Table 22. Level of Recommendation Concerning Monotherapy during the Maintenance Phase and in Relationship to Index Episode, Composi-
tion of the sample, Presence of Rapid Cycling and the Efficacy in the Prevention of Mainic, Mixed or Depressive Episodes as Well as Recom-
mended Dosages
Agent/modality Index episode Enriched sample Manic Depressive Mixed Rapid cycling
Recommended
dosage
Quetiapine m/d Yes 2 2 - Quet+ Val/Li (3) 300–800 mg/d
Olanzapine m Yes/No 2 2 2 - 5–20 mg/d
Lithium m/d No 2 3 - Li, Li + Cbz (3) 0.6–1.2 mEq/L
Lamotrigine m/d Yes 3 2 - 5 50–400 mg/d
Aripiprazole m Yes 1 5 - 3 10–30 mg/d
RLAI m Yes 1 5 - RLAI+TAU (3) 25–50 mg/biweekly
Paliperidone m Yes 2 5 - - 3–12 mg/d
Valproate m Yes 4 3 - - 45–100 mg/L
Ziprasidone m Yes - - - - 80–160 mg/d
Perphenazine m Yes - - - -
Imipramine d ? 5 5 - -
Fluoxetine d Yes - 2 - - 10–40 mg/d
CBT d No - - - -
N-acetyl cysteine d Yes - - - -
Carbamazepine - - 4 4 - Li + Cbz (3) 4–12 mg/L
Abbreviations: CBT, cognitive behavioral therapy; Cbz, carbamazepine; Li, lithium; Quet, quetiapine; RLAI, Risperidone Long Acting Injection; TAU, treatment as usual; 
Val, valproate.
Enriched sample: the sample is enriched on the basis of remission after treatment with the agent under consideration during the acute phase (index episode).
Table  23. Level of Recommendation Concerning Combination 
Treatment during the Maintenance Phase
Agent/modality MS Cbz Lam Li Val
Quetiapine 1 - - - -
Aripiprazole 2 - 5 - 5
RLAI 2 - - - -
CBT 2 - - - -
Phenytoin 2 - - - -
Paroxetine 3 - - - -
Psychoeducation 3 - - - -
Olanzapine 4 - - - -
Ziprasidone 4 - - - -
N-acetyl cysteine 4 - - - -
Imipramine - - - 5 -
Memantine 5 - - - -
Oxcarbazepine - - - 5 -
Lithium - - 4 - -
Perphenazine 5 - - - -
Abbreviations: CBT, cognitive behavioral therapy; Cbz, carbamazepine; Lam, 
lamotrigine; Li, lithium; MS, mood stabilizer; RLAI, Risperidone Long Acting 
Injection; Val, valproate.
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For acute bipolar depression, the NICE recommends olan-
zapine, OFC, quetiapine, lamotrigine, lithium, and valproate. 
If the patient is already under treatment with lithium or val-
proate then the recommendation is to increase the dosage to 
the highest permitted, and reassessment should follow before 
the changing of medication. The next step includes combina-
tion of lithium or valproate plus quetiapine or OFC. The third 
step includes lithium plus lamotrigine or olanzapine and val-
proate plus lamotrigine. The NICE warns against the use of 
gabapentin and topiramate.
During the maintenance phase, the NICE guidelines recom-
mend as first line treatment the continuation of the treatment 
the patient received during the acute phase and led to the reso-
lution of the symptoms. Irrespective of predominant polarity the 
continuation of this treatment should be done for at least 3 to 
6 months. In case the patient does not wish to follow this, it is 
recommended to change treatment to lithium, olanzapine, que-
tiapine, valproate, or lithium plus valproate. Again, NICE warns 
against the use of gabapentin and topiramate.
The procedure and the interpretation of evidence as presented 
in the NICE guidelines have been criticized (Jauhar et al., 2016).
Efficacy, Recommendation Level, and Precise 
Treatment Algorithm
The detailed table of the efficacy level for all treatment options dur-
ing all phases and against specific features of BD is shown in web 
appendix 1. The detailed table of the recommendation level for all 
treatment options during all phases and against specific features 
of BD is shown in web appendix 2. Add-on and combination data 
were merged for the sake of simplicity. Additionally, the detailed 
precise algorithm that was developed is shown in web appendix 3.
The levels of recommendation concerning monotherapy in 
acute mania and recommended dosages for medication options 
are shown in Table 11, while the recommendation levels for com-
bination treatment are shown in Table 12. Recommendation lev-
els concerning treatment options for rapid cycling patients are 
shown in Table 13 and the effects on concomitant depressive and 
psychotic features are shown in Table 14. The recommendation 
levels for monotherapy and combination treatment in patients 
with a DSM-IV-TR mixed episode and the specific effects on the 
manic and the depressive component are shown in Table 15 (pro-
vided here for academic reasons).
The chart of the algorithm for acute mania/hypomania on the 
basis of strict evidence and by taking into consideration specific 
clinical features is shown in Table  16. The comparison of this 
algorithm to previously developed guidelines for acute mania is 
shown in Table 17.
The levels of recommendation concerning monotherapy 
in acute bipolar depression, in comorbid conditions, and rapid 
cycling patients and recommended dosages for medication 
options are shown in Table 18, while the levels of recommenda-
tion concerning combination treatment are shown in Table 19.
The chart of the algorithm for acute bipolar depression is 
shown in Table  20. The comparison of this algorithm to previ-
ously developed guidelines for acute bipolar depression is shown 
in Table 21.
The levels of recommendation concerning monotherapy 
during the maintenance phase and in relationship to index epi-
sode, composition of the sample, presence of rapid cycling, and 
the efficacy in the prevention of manic, mixed, or depressive epi-
sodes as well as recommended dosages are shown in Table 22, 
while the levels of recommendation concerning combination 
treatment during the maintenance phase are shown in Table 23.
The chart of the algorithm for the maintenance phase is 
shown in Table  24. The comparison of this algorithm to previ-
ously developed guidelines for the maintenance phase is shown 
in Table 25.
Overall the algorithm consists of the stepwise approach in 
Tables 16, 20, and 24 and in web appendix 3.  However, a more 
fundamental approach would be to utilize web appendix 2 that 
includes a table with the recommendation levels by clinical indi-
cation for all the treatment options. The utilization of this table 
could be more precise and accurate in comparison with the step-
wise description. Until then, the clinician can handle the table in 
a manual way. First he or she should decide on the phase of the 
disorder (acute manic vs mixed vs depressive episode vs mainte-
nance phase). Then he or she should choose the combination of 
the clinical features under the specific phase and finally he or she 
will identify that treatment options best fit the clinical syndrome. 
For example, if the patient is in an acute manic episode with some 
accompanying depressive symptoms (mixed features) and psy-
chotic symptoms and his or her history suggests he or she is also a 
rapid cycling, then the only agents that treats all these conditions 
are olanzapine and quetiapine followed by lithium that is second 
choice. If the patient is BD-II in a depressive episode with anxiety, 
then the only suitable agent is quetiapine. Of course such an algo-
rithm might be too restrictive; however, the clinician can use the 
table to produce combinations of treatment options to satisfy all 
clinical needs on the basis on research data.
Discussion
The current paper represents a systematic search of the litera-
ture on the treatment of BD. By using an established approach 
we identified all relevant RCTs pertaining to all faces and spe-
cial issues of BD and graded the data according to a predeter-
mined method. Finally, a recommendation level was assigned 
to all treatment options depending on the clinical situation.
It was interesting to see that except for rare cases, the con-
cept of mood stabilizers is not supported by the available data, 
especially for those agents traditionally considered as such.
It is obvious that, by far, the body of evidence originates from 
RCTs that were conducted with agents that have been launched in 
the last 2 decades. This constitutes a significant bias in the literature, 
and one should be cautious in the way that the accumulated clinical 
experience concerning those agents and treatment modalities with 
poor evidence-based support should also be taken into account.
A low grade of evidence for these old and poorly studied 
agents and modalities (e.g., carbamazepine, clozapine, ECT, etc.) 
does not necessarily mean a lower effectiveness and safety in 
comparison with other drugs, but it still implies that the clini-
cians should be cautious in their application in patients with BD. 
Yet it is irrational to use different standards; on the one hand to 
study carefully and seek flaws in the design of major RCTs and 
on the other hand to accept a wide recommendation of agents 
with poor evidence-based support because of historical reasons. 
The authors of the current paper spent much time and effort to 
grade the agents on the basis of quantitative but also qualitative 
characteristics of the data available. This effort resulted in the 
development of a precise algorithm on the basis of a reproduc-
ible methodology.
Also, the results on those areas of interest that are not 
targeted as primary outcomes are reported in a nonsys-
tematic way and therefore the grading of evidence is lower. 
Unfortunately these areas constitute the overwhelming clini-
cal picture of BD.
As with many other guidelines, the inherent limitations of the 
literature as well as the unavoidable subjectivity of experts when 
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Table 24. Precise Algorithm to Treatment during the Maintenance Phase for BD on the Basis of Specific Clinical Characteristics
Step First Second Third Fourth Fifth
Depressive 
predominant 
polarity or
No predominant 
polarity
Quetiapine or 
olanzapine 
monotherapy
Add fluoxetine or 
lamotrigine
Add N-acetylcysteine If depressive episodes 
keep emerging add 
an agent with proven 
efficacy against acute 
bipolar depression no 
matter whether it has 
proven maintenance 
efficacy. Consider 
adding venlafaxine 
or lithium plus 
lamotrigine.
Consider any 
combinations from 
steps 1–4 that have not 
been tried.
Consider maintenance 
ECT
Various combinations of 
medication according to 
anecdotal knowledge or 
the personal experience 
of the therapist
Consider IPSRT as add- 
on to medication 
on the basis of 
clinical judgement 
of the therapist and 
according to the 
patient preference and 
to availability. Never 
consider IPSRT as 
monotherapy
Manic 
predominant 
polarity
Start with lithium, 
aripiprazole, 
olanzapine, 
paliperidone, 
quetiapine or 
risperidone 
(including RLAI) 
monotherapy
Add lithium on the 
first step option
Lithium plus 
carbamazepine
Quetiapine plus 
lithium or 
valproate
If manic episodes keep 
emerging add RLAI on 
current treatment if 
not already in place
Add N-acetylcysteine
If manic episodes keep 
emerging add an 
agent that has proven 
efficacy against acute 
mania no matter 
whether it has proven 
maintenance efficacy. 
Consider haloperidol 
or lithium plus 
lamotrigine
Mixed episodes are 
frequent
Olanzapine or 
aripiprazole plus a 
mood stabilizer
Add valproate, 
carbamazepine, or 
lamotrigine on second 
step treatment
Proceed to next step
Rapid cycling Lithium monotherapy
All cases Consider CBT or psychoeducation as add-on to medication on the basis of clinical judgement of the therapist and 
according to the patient preference and to availability. Never consider CBT or psychoeducation as monotherapy
Abbreviations: CBT, cognitive behavioral treatment; Cbz, carbamazepine; ECT, electroconvulsive therapy; IPSRT, InterPersonal and Social Rhythms Therapy; Lam, 
lamotrigine; Li, lithium; MS, mood stabilizer.
Table 25. Comparison of the Presise Algorithm to Previously Developed Guidelines for Maintenance Phase Concerning Monotherapy
CINP
2016
WFSBP
2013a
CANMAT and
ISBD 2013 NICE 2014b
BAP
2016b
Aripiprazole 1 1 1 - 3
Lithium 1 1 1 1 1
Olanzapine 1 2 1 1 2
Paliperidone 1 3 2 - 3
Quetiapine 1 1 1 1 2
Risperidone 1 2 - - 3
RLAI 1 - 1 - 2
OFC 2 - 2 - -
Lamotrigine 2 1 1 - 2
Carbamazepine 3 4 2 - 2
Valproate 3 3 1 1 2
Haloperidol 4 - - - 3
Venlafaxine 4 - - - -
ECT 5 4 3 - -
Ziprasidone 5 3 - - 3
Continue most recent episode treatment NR - - 1 -
Antidepressants - 3 NR - 4
Asenapine - 4 3 - 3
Gabapentine - 4 NR NR -
Topiramate - 4 NR - -
Abbreviations: ECT, electroconvulsive treatment; NR, not recommended; OFC, olanzapine-fluoxetine combination; RLAI, Risperidone Long-Acting Injectable.
The grading is not uniform; instead it reflects the grading utilized by individual guidelines and the Table aims only to give an image of how different guidelines 
prioritize treatment options.
Numbers correspond to steps not to efficacy ranking.
a WFSBP: Recommendation grades and subsequent positioning could be either based on efficacy in the prevention of mania, depression or any episode. Thus, num-
bers do not reflect the sequence of treatment in an individual patient.
b NICE and BAP ordering is on the basis of line of treatment.
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making a recommendation (even when based on evidence) should 
be taken seriously into consideration by the clinicians when read-
ing the current paper. Also negative results (level 5)  should be 
taken very seriously into consideration, as they should be consid-
ered to be scientifically stronger in comparison with positive ones.
Further limitations include the heterogeneity of the RCTs 
that served as basis for the recommendations and the lack of 
trials assessing specific subpopulations, following the rules of 
stratified medicine (Schumann et al., 2014), or applying staging 
methods to psychopharmacology (Grande et al., 2015), in search 
of more precision when treating individual patients (Vieta, 2015). 
However, these CINP guidelines represent the most up-to-date 
effort to condense the current knowledge on the management of 
BD from an international perspective.
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